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The interventions Wllicll are shown to decrease malaria effective 
antimalarial treatment and intensive care supportive management of malaria 
are not accessible to a considerable 
areas, particularly in rural Africa. 
of those living in malaria endemic 
To evaluate the of absorption, antimalarial efficacy and tolerability of a rectal dose 
of artesunate in the initial "f'l'~ITl,ont of non immune adults with moderately severe and severe 
malaria. 
Methods: 
of and antimalarial of a rectal administration of artesunate 
(10 mg/kg) were assessed by rate of decrease in asexual clinical 
response and area under the time curve of artesunate and its active 
mrIVrlrn;UT~'rnISlrllfl. To compare artesunate with standard n:lrpr,tp,r:o one in five 
was allocated to As soon as POSiSlbie after 24 both 
artesunate and quinine groups were treated with a single dose of 
(1.25 
Results: 
Arnong the adults with 
60 0ft) of baseline 
treated group 





patients with severe malaria. Parasite 
at 12 hours was 
with 5/8 [63 ry,J 
than 
in the 
p<O.001]. This difference between treatments were 
reduction in 
at 12 hours was 
was not 











(40%) in artesunate arm with 5/6 (83%) in the arm; 0048 (0,15-1 
9)J, Clinical response was with rectal artesunate and both in 
with severe malaria and those with severe malaria, 
Artesunate and 1 or its active dihydroartemsinin, were detectable in the 
between 1 and 8 hours after administration in all 27 with severe malaria and 
four of five patients with severe malaria, There was marked inter-individual of the 
of artesunate and 
ie effect in terms of 
Measurable drug exposure could not 
or clinical response to treatment 
Artesunate was generally well tolerated at 10 administered in the small cohort 
stud ied, The of serious adverse and of adverse events overall, did not differ 
nervous 
studies. 
between artesunate and control groups. 
did not detect of abnormalities 
evaluation of the central 
described in dose animal 
A sin(Jle rectal dose of artesunate is to be a useful for initial treatment of patients 
with severe malaria unable to tolerate oral medication, particularly where 
treatment is not readily available. 
artesunate in with severe 
further studies of the 
malaria are needed. 
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Study Aims and Objectives 
1 : aims and 
aim 
This ttlesis aimed to the of of a administration of 
in non-irnmune 
malaria. Such patients are 
artesunate (10 over the initial 24 hours of 
Cld u Its with severe or severe Plasmodium 
unable to tolerate oral medication, and in many malaria transmission areas do not have 
access to treatment. The to be tested was that the administration of 
rectal artesunate would provide adequate initial antimalarial cover, indicated by a rapid fall in the 
of and that this would be achieved without clinical deterioration and wittlout 
serious adverse reactions. If this were to be confirrned, rectal artesunate be 
recommended as a 
reach a health care 
treatment to enable a unable to tolerate oral medication, to 
where treatment could be ad min istered . 
Adult presenting to Mosvold hospital or its satellite clinics in northern KwaZulu Natal with 
either: 
.. severe malaria who were treated with either a 
administration of rectal artesunate or ron",..,.tan administration of intramuscular 
followed in both treatment anns by a administration of sulfadoxine-pyrirnethamine 
at 24 hours (or as soon as or 
II severe malaria who were treated with either a administration of rectal 
artesunate PLUS intravenous alone, followed in both treatment arms by a single 











Aims and Objectives 
1. To determine the of hcrwnir.nn of a dose of rectal artesunate in terms of: 
i) Rate of clearance from the blood defined reduction in 
parasite density 12 hours, by 24 hours and clearance time. 
ii) The clinical response to treatment defined by fever clearance time, time to tolerate 
oral case rate and, in with severe 
to severe malaria. 
iii) Plasma levels of artesunate and its metabolite dihydroartesunate as rneasures of the 
of 
2. To compare a 
q 
L Rate of 
dose of rectal artesunate with best available standard 
in terms of: 
clearance from the 




iL The clinical response to treatment defined by fever clearance time, time to tolerate 
oral med case rate and, in with severe 











2 Literature Review 
Introduction 
Almost all of the over one million malaria related deaths are attributable to Plasmodium 
Health 2000). The and of severe, 
malaria can be identified by rural health workers and even by (Kidane and Morrow 2000). 
in ,pr'pl\,·,nn effective medication is an contributor to the malaria 
rate, As a considerable of with acute malaria are unable to tolerate 
oral to or increased disease CO"Pn'H treatment is often 
necessary, Unfortunately, few rural Africans have access to health facilities that are to 
provide treatment Malaria morbid and is further as a result of 
the resistance to the most used and 
1998). There is a clear need fo r an effective d rug that can be 
administered simply at village or rural health centre level to those unable to tolerate oral 
to transfer to a healthcare where treatment can be The 
of a thermostable formulation for rectal of artesunate offers the 
antimalarial cover to in the periphery, who are unable to tolerate 
oral medication, while are transferred to healthcare facilities able to 
treatment 
Plasmodium malaria can manifest as 
disease to severe ,ro_,thr",,,·ton disease. In severe is 
to range between 1 with the higher rates usually seen in studies with more 
rigorously defined severe malaria (Wond Health 2000). of patients as 












which do not have the 
renal failure or adult distress 




2000). This has 
severe malaria used in this 
n'>T,cm',c who are at increased risk of severe malaria without 
for those 
crrteria. 
rates from one fonn of severe malaria 
malaria) was 3% (Luxemborger et al 1 with under 1 %.1 in malaria 
et al 2003) and 10-40% in severe and complicated malaria (World Health 
Conventional for severe in addition to h level of ,nn,l"\rt'",,,,,, care available, 
is quinine. This requires either constant rate infusions or painful 
intramuscular is associated with et al 1 
and has a narrow 
Four randomised controlled trials have intramuscular artemether with 
van Hensbroek et al 1 Hien et 311 et al1 
clearance of 
et al 1 
Fever Artemether was associated with a more 
clearance times were more rapid with artemether in one study, and similar or slower in the other 3 
studies. In the 2 artemether was associated with a recovery fram coma, 
which is to be . This , which remains a cause for concern, was 
not evid ent in a of artemisinin derivatives for the treatment of severe malaria, which 
showed no difference in neurological This included 2653 
in 16 trials artemisinin derivatives with found that the artemisinin d rugs were 
associated with better survival odds ratio 0.61; 0.46- 0.82, random effects model). This 













The early of modem intensive care, haemofiltration rather than 
in or malaria related acute renal and pressure ventilation is 
to contribute to 
very seldom available to those at 
treatment to prevent at risk patients from 
Artemisinin derivatives 
a lactone 
Unfortunately these resources are 
the need for early effective 
to severe malaria. 
is the active antimalarial moiety isolated from the 
traditional Chinese medicinal herb Artemisia annua. Artemisinin annua has been used for many 
years the Chinese as a traditional treatment for fever and malaria. Artemisinin and derivatives 
were tested extensively in China Antimalarial Research These are the 
most rapidly of all antimalarials 1993). Artemisinin and its derivatives are 
distinct from other classes of antimalarial and are thus not vulnerable to cross resistance 
and are effective even re recrudescent multi-drug resistant P 
etaI1998). 
The mechanism of action of artemisinin and its derivatives is not understood, 
the of this on an intact is established. Eckstein-
and have shown that the artemisinins work through a 
metabolic enzyme, the Plasmodium ent ATP-ase (PfATP6) which is 
situated the parasite cytoplasm, an mechanism which 
"""-"''',." free radicals from artemisinin. This inhibition of PfATP6 results in a of 
U et 2003). This evidence contradicts previous theories that the 
specific antimalarial effect of artemisinins was due to its accumulation in the food 













Two of the artemisinin derivatives have been evaluated more artesunate and 
artemether. Both the water-soluble artesunate and the soluble artemether derivatives are 





as do not have an intact 
The 
All artemisinin 
of a single dose of 
in with liver cirrhosis were not different from results in 
that there is no first pass effect (Duc et al 1 de Vries et al 
The areas under the time curve of artemisinin and artesunate have been shown to 
decrease after oral , which is considered a result of increased 
or an auto inductive effect (Ashton et al 1998, Khanh et al 1 All metabolites 
further ation and are excreted in the urine or faeces data on excretion is 
artemisinin and its derivatives are all Iy eliminated, they have been shown 
to be ",m"','T'''''' wtlether 
of 
suitable assay. 
once, twice or three times (White 1 
is to with the 
of artemisinin derivatives occurs in 
the need for immediate centrifugation and cold (Navaratnam et al 
dihydroartemisinin accumulates in 
p",C\"".."nQnT of a 
Fu 
than 300-fold 
concentration than the co ncentratio n, with only 2-fold in 
uninfected eryth in vitro) (Gu et al 1 This accumulation is reversible and saturable. 
The artemisinin derivatives appear to have a wide index the exact 
and toxic levels in tlUmans remain to be defined. Thus the doses of artemisinin 
derivatives used have been derived (Rowland 1995). adult 
with acute fa/ciparum malaria in Thailand, no further reduction in parasite 
clearance times was found with use of single oral doses of artesunate than 2 mg/kg, 












The artemisinin derivatives have tile rates of clearance of all the antimalarial 
This has been 
broadest number of 
by their potency and the fact that their covers the 
in the asexual part of the life 
cycle of known antimalarials Kuile et al 
in more severe 
endothelium 
into more mature 
In this way, 
microvasculature of vital organs is reduced 
et al1 
Artemisinin and its derivatives have the 
principally on young 
which adhere to the vascular 
of in the 
artemisin but not 
Aliemisinin and its derivatives have been administered as and have 
been shown to 'COTc'nT'''' result in a and clinical response, 
is more erratic this route of administration when 
Ha et al 1 with intravenous administration et al 1 
When used as artemisinin derivatives are associated with a recrudescence 
unless administered for 7 
10% - 20% recrudescence after 
28% - 40% recrudescence follows monotherapy, with 
et al 1996). Recrudescence rates are 
eta11991, Lietal1 
Artemisinin-based combination 
In addition to benefits in terms of 
artemisinin based combinations 
to d the emergence and 
tuberculosis and H and should 
monotherapy (Borrman et al 2002, Alin et al 1 Hassan 
in non-immune 
resistance and 
clinical cure rates. The 
in Thailand and China 
malaria transmissio n, 
of combination 
of resistance is established in the management of 
well to malaria 
demonstrated with the combination of artesunate with 
This has been most 












western Thailand with low malaria transmission and strict control of access to these antimalarials 
et al The benefits of when used in combination with a second 





in the of 
PTTlr'-::lr'\I has resulted in the 
in the treatment of 
are used in combination with 
malaria. Confinnation of clinical 
use of artemisinsin based combination 
resistant malaria in Thailand and Vietnam where 
'"/,\C'TC''' et al 1994, Price et al 1 
This has been followed more 
recommended as first line treatment of 
with artemisinin-based combination 
malaria in South America 
and in Africa KwaZulu Natal, and Zanzibar) ,",':len",.C' and Baker 
As the artemisinin derivatives are the most of all anti-malarial and reduce the 
biomass by 10 000 fold per sexuallifecycle, they would protect 
vulnerable anti-malarials (those wrth a terminal elimination half a shallow 
concentratio n-effect 
marked reduction in 
and I or those in which a few base mutations confer a 
the of resistance 
Concomitant oral administration of arte unate however, result in significant changes to 
mefloquine kinetics in with the clinical effects of this 
of the combination has been sustained for over a effect is not established and the 
decade rn"lIo,,',n et al 1994, Nosten et al 2000). Similar effects on the kinetics of sulfadoxine-
have not yet been 
It is of that artemisinin derivatives also reduce and 
thus reduce the transmission of malaria, and particularly the transmission of resistant strains of P 
1996). Recrudescent infections are associated wrth increased 













altematives has been frequently described 
resistance of P to all available 
The and of artesunate in combination with sulfadoxine / has 
been evaluated in randomised controlled trials 2685 in sub Saharan Africa. 
Results from the first study published from the Gambia (von Seidlein et al 2000), where the 28-
cure rate with SP was showed that cure rate and clearance was 
in who received 3 of artesunate PLUS a stat dose of SP when 
to those who received SP was 68%, SP 
monotherapy treatment in to 21% following combination treatment (p:::: 0.001). 
of artemisinin derivatives 
Artemisinin and its derivatives are considered safe and well tolerated. Most of the 
concems the of artemisinin derivatives derive from animal studies or mild to 
moderate adverse events that have been from clinical studies. The artemisinin 
have been used especially in SE for the treatment of P with 
very little evidence of and Olliam 1998, Price et al 1999). However only a few 
studies have included young children, in whom malaria is most prevalent in and this 
or no active apparent is undermined the use of counterfeit with 
detect 
et al 2001). Careful clinical 
rrm"lVIi',Y\I has failed to detect deafness or 
auditory evoked were normal in all 
2000b). Concerns about nnt"pnt"i::> 
to the brainstem nuclei induced 
artemether and arteether in animal studies 
dose 
~pn"""~<.:.., et al 1 
examination in studies 
et al 2000, van 
rcr,nrl'e of an unusual 
for 14 






al 1 Brewer et al 1998). Although coma time was observed in two of three 
randomised controlled trials artemether with quinine in the treatment of cerebral 












treated (Mcintosh of 28 fatal severe malaria cases eXIJm;ea to either 
artemisinin derivatives or quinine found no evidence of neurotoxicity (White NJ, 
There have been case of fine 
motor coord and seizures following treatment of severe fa/ciparum malaria 
with an artemisinin derivative (Miller and Panosian 1 Elias et al 1 concomitant 
administration of uine and malaria itself may have caused these 
(Davis et al 1 White 2000). In animal studies, artesunate 
than artemether and arteether Health 
Clinical studies have rar,nr"'''' and mild skin rash in 1-4% of 
abnormalities 
has shown less 
2000). 
artemisinin-
based combination therapy, with tile higher incidence observed with the concurrent administration 
of et al Price et al 1 et al 2001, van et al 
Two cases of severe reactions to artesunate have been rar,nrta,., in Thailand, 
from whicll the authors Ilave calculated a risk of 1 in 2833 confidence intervals 1 
et al 2001). Concomitant use of medication that can cause skin reactions as 
or HIV infection may increase tile risk of such reactions. 
animal studies have shown a 
neutropenia and a decreased 
may be attributable to 
C:\/<::tArn:::>Ylr review rar,nrta" 





and Olliaro 1 
these results have not been recent studies which may be limited by their small 
size and exclusion of at risk of neutropenia Bakshi 
et al 2000, LeFevre et al 2001, van et al 1 
of to date. HIV infection, 
may further contribute to haematological 
countries may increase tllis risk. 
Price et al 
amod 
and their 
There have been no 
and antifolate drugs 












There have been no of In to 
careful ECG 
aaE~stE~d small 
artemisinin there were no card iac effects 
Other stud ies have 
in the OTc 
less cardiotoxic than 
but these appear to be no different to other antimalarial 
and et al LeFevre et al 2001, Price et al 
Animal studies have shown 
artemisinins administered 
and even with low doses of 
; artemisinins are also associated with significantly 





to artesunate plus SP in comparison to those not ; there was no 
of abortions or neonatal deaths 
of women treated with artemisinins in 
there was no evidence of adverse effects and birth outcomes did not differ 
rates for abortion, or 
2001), these studies that artemisinins may have a 
pregnancy, 0 n Iy 80 of the women stud ied were the first trimester. 
Artesunate 
most studies in severe malaria have evaluated artemether or '::In-,"oTl',or rather than 
artesunate et al 1992, Win et al 1992, Hien et al 1 Boele van Hensbroek et al 1 
Taylor et al 1 Pittler et al 1999, Phuong et al 1 Newton et al 2003), 
intramuscular artemether may not be the most suitable formulation with severe 





artemether is an oil-based formulation that is converted 
and absorbed intramuscular administration in ill 
World Health There is evidence tt1at 
in children with acidosis et al 1 in 












administered and is more absorbed than artemether if administered 
Clinical and parasitological response was shown in a small to be similar in 
n!:>t.",n·r<: with severe malaria intravenous or intramuscular administration of 
artesunate followed by 1 at 12 and 24 hours et al1 Secondly, in animal 
studies artemether and arteether were found to be more neurotoxic than a 
than water-soluble derivative et al 1 artesunate is more 
artemether: artesunate and its active metabolite DHA have in vitro antimalarial activities 2.9 and 
4.0 than respectively et al 2000), active are 
the of artesunate in in an acid (Newton et al 
Recent case reports that artesunate also has a diuretic which may 
distress additional benefit in patients with acute renal failure and adult 
et al Artesunate is thus in severe although there 
or artemether. has been no trial intravenous artesunate with either 
A of intravenous artesunate and in 113 adults with severe malaria 
of 12% with artesunate and 22% with quinine et al Oral 
artesunate was found to be clinically and to intravenous quinine, in 
"""an'''' with malaria with than 4% """"'c,""''''' et al1 
There are a number of small studies on the clinical efficacy of rectal artesunate in adults with 
severe P infections et al 1 Eduardo et al 1 Thwe et al 1 
Looareesuwan et al 1 Looareesuwan et al 1 In each of these 
<:;;I-'c,cac;uly and was combined rectal artesunate was administered with a 
second oral antimalarial to nro.,,,:,,,, recrudescence of malaria. These data are summarized in 




cure rate at 28 
which include 
cerebral 
clinical criteria of 
These studies 
and 
regimens of increased 
used the WHO definition of 
the more 
The use in some of these 












associated with a poor 
and of these studies with studies of 
rectal artesunate followed 
et 31 
of rates between ttlese studies 
or sulfadoxin 
hemisuccinate derivative of this 
of The detailed 
Artesunate is a 
enhances its 












with Electro-chemical detection 




in quantitative determination in 
Artesunate has an elimination half-life (t~,) of 2-5 while DHA has a t .. , around 40-60 
minutes et al 1 et al 1 Davis et al 2001, Newton et al The short h, of 
artesunate that its o .... ',.."r·" is due 
insufficient data to describe artesunate kinetics in the 
Volume of distribution of artesunate of 0.08 and 0.14 
to the action of DHA. There was 
of studies. Two studies a 
et al 1 Davis et al 2001); 
et al an artesunate AUC of 2.98 I-lMol.h/L. 
The of d artesunate oral or intravenous 
administration are summarized in Table 2. In with the 
relative of d roartemisinin after oral administration of artesunate is 82% of that 
following intravenous 
DHA using a sensitive 
convalescence 
and the oral bioavailability of combined artesunate-
was 61 % in the acute double that found 
et al 
median time and earlier median 
Artesunate is absorbed with a 
antimalarial than DHA et al 
shorter 
This 
probably reflects the faster dissolution of the water-soluble artesunate tablet relative to the 
insoluble DHA tablet. The clinical of these differences is not established. 
Davis et al 1) concluded that disease did not alter the of 
intravenous artesunate in ttleir of patients with either severe 12) or 
severe malaria (n:::8). In this small study a trend to a shorter clearance time with 











of ::>rOllrn<,tAlrc: of the active metabolite d 
after initial administration of influential characteristics. 
all artesunate and dihydroartemisin was cleared within under 10 hours of artesunate 
administration et al 1 Ittarat et al 1 Newton et al artesunate is 
effective whether administered once or twice et al 1991). This 
that rapid clearance can be achieved after a relatively brief exposure to artesunate and 
its active metabolite. 
Artesunate can be administered orally or rectally. Rectal artesunate is rapidly 
absorbed there is considerable interindividual variation (Benakis et al 1 It has been 
shown to be safe and effective in children and adults with 
malaria Sabchareon et al 1 Two 
of (range 0.86-2.55 
studies have 












Gabonese children with malaria Bet al 1998), and of 10 vs rectal 
artesunate in 34 Ghanaian children with severe S et 2001). 
The selection of a 1 dose for th is 
in which rectal artesunate was more 
was based on find 
absorbed in the 1 




and the median relative bioavailability of DHA was in the 10mg/kg than 
variation in the vs there was wide 
and 20-fold 1 rectal Cmax 
was higher (5-fold) following IV than rectal parasite clearance kinetics were 
with 2.4 IV artesunate for both and 20 rectal artesunate 
groups. Arteslinate was eliminated more Iy and Volume of distribution 
smaller IV artesunate than reclal artesunate S et 2001). In the 
other of artesunate rectal administration 
(in children with only the CMax (0.09 for artesunate and 0.18 for 











of Literature ... "".,", .. and for thesis. 
Although artesunate has theoretical advantages over both 
"n,=>n<>,n,pnt of more severe ind ivid ual stud ies have 
more clearance. 
and artemether for the 
shown clinical equivalence 
There are no stud ies of the of 
with 
and of a 
dose of rectal artesunate in adult 
stud ies have 
severe or severe malaria. Pilot 
of reclgl artesu nate in 24 
Ghanaian children with severe malaria. Evidence of the of 
repeated admininstration of rectal artesunate in severe and evidence that artemisinin 
derivatives are effective whether once, twice or three times the 
evaluation of a dose of rectal artesunate in with more severe malaria. 
since is not established, such a should be conducted in a facility where careful 
monitoring and supportive care can be provided. 
The dose of rectal artesunate was selected based on the 
data made available to the clinical and response 
of 10mg/kg of rectal artesunate to that of both 2.4 mg/kg intravenous and 20 mg/kg rectal 
as was Krishna et al ). 
the single dose of rectal artesunate evaluated in the is less likely to have 
toxic effects than a full treatment course, it is important to monitor 
those identified. Given that serious adverse 
for adverse 
reactions are 
to be uncommon on the low incidence in clinical trials and this 
is not nm,,,p,rpn to draw conclusions the of rectal artesunate. There is 
insufficient evidence of the of artemisinins in pregnancy, particularly in the first to 











Current knowledge of the 
artemisinin derivatives occurs in 
in 
of artemisinins is incomplete. of 
and 
levels should be WITh 
caution. The therapeutic range of artemisinin derivatives including artesunate is poorly defined, 
and are 
this artemisinin derivatives show more 
rectal administration. 
reduction in 
when absorbed than all other classes of antimalarials. Thus 
evidence of reliability of should be considered of secondary importance to 
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This was a Phase III randomised PK / PO n<l,",e:rm between rectal AS and 
rantor",1 quinine in southern African adults with moderately severe or severe malaria. 
Patients were stratified into the severe and severe malaria 
criteria below). basis of their disease 
severe IClIIALJ,W malaria: 
Randomised to receive either: 
on the 
artesunate suppository followed by 
1 ) 
/ pyrimethamine at 24 hours 
or 
intramuscular quinine followed sulphadoxine / pyrimethamine at 24 hours, if 
able to tolerate os" medication 
Severe and .. .m...,."""." malaria 













The was conducted at Mosvold District in northern KwaZulu South 
Africa, which serves a non-immune resident in an area with low 
Inoculation Rate < 1), seasonal malarial transmission, which 
between and one small in vivo had been conducted in the 
area, which demonstrated 18% resistance to in 1997: ( RI: 
RII: Rill: 2.9% (n :::: ') which is has been treatment for 
uncomplicated malaria in KwaZulu Natal since 1998. 
Discussion of 
The randomised controlled was chosen to allow estimates of relative and 
in to the best available in H18 
intravenous often, intramuscular) quinine is not accessible in most rural malaria 
endemic areas where rectal artesunate is most needed, is considered 
the of choice in the Allocation ratios were chosen to 
maximise the collection of data on artesunate SUPPOSITory and pharmacokinetics, 
while a reference group standard of known and 
Rectal artesunate is intended for emergency use to antimalarial cover for the 
in itial 24 hours to enable unable to tolerate oral medication to reach a health 
where safe treatment is available. As rectal artesunate is intended as 
an initial intervention and not as curative and short courses of both 
artemisinins and are associated with 
Classification describes parasitological responses with 
eliminated drug; RI: In patients appear cured as 
detectable whereafter reappears 
decreases but fails to clear within 7 
density by 72 hours. 
, all 
levels of resistance to a 
density decreases below 
with 
re-infection excluded RII' 











Chapter 3 Methods 
severe malaria received identical treatment with recommended first line 
thereafter. 
In those with severe 
after 24 hours or as soon as 
in addition to a stat dose of SP to 7 
of ine was rnn'C>T<::'" to minimise the risk of treatment failure. 
In an area with a similar intensity of malaria transmission to KwaZulu the risk of 
death in with severe malaria (> 4% and no vital organ 
with 0.1 % in all , and 18% in 
severe 
size calculations 
This is a of a multicentre on which the WHO aims to recruit 300 
size calculations to est blish of in the 
local population were as follows: 
For with severe malaria: a at 24 hours of 
5°1c) that at baseline in treated with rectal artesunate and of 30% for 
treated with 1M quinine, a sample size of 43 per treatment arm is needed to achieve 
at the 5% level with 80% power. 100 
that at least 86 follow up. 
For with severe malaria: a 
baseline in treated with rectal artesunate 
were to be recruited to ensure 
at 24 hours of 10% that at 
IV quinine and of 50% for n-:>t,an1tc 
treated with IV quinine a size of 24 per treatment arm is needed to achieve 
at the 5% level with 80% power. 50 were to be recruited to ensure 














For all groups: 
• 16 - 65 years 
• P. clinically suspected, with a positive ICT® 
card confirmed with a nn,,,tn,l(:> P thick smear. 
• Patient or or informed consent. 
• PLUS at 
For groups 1-2 severe 
the considered oral 
features of severe and malaria - see below) is: 
• Unable to eat or drink 
• Iy 
• rated 
• Prostrate to stand I walk 




• Jaundice (detected 
rate> 20 and HC03 < 15 




• Bleed disseminated intravascular 
• Shock blood pressure < 80 with of poor 












II Decreased level of consciousness to localise or make verbal 
response to a noxious at least 30 minutes after a 
II Serum Lactate level> 5 mmol/L 
.. Plasmodium falciparum asexual 
II Renal failure < 400ml in 24 
I I) 
.. (defined as a whole blood 
> 500 000 I pI. 
or a creatinine of more than 265 
concentration < 2.2 mmoI/L); 
Exclusion criteria 
.. Diarrhoea (defined as > 2 uid stools in the previolls 
.. A of received an effective anti-malarial in the 24 hours 
II Beta-HCG card test in all female patients) or breast 
women 
.. Diseases of the rectum, previous rectal surgery. 
.. A history of 
with a 
to artemisinin derivatives or quinine 
reactions to 
were to be included in the 
instead of sulphadoxine I n",'''YlOTn 
or any 












Criteria for withd rawal from treatment or assessment 
Groups 1 & 2 
Patients in 
icated 
the 24 hour 
& 2 who failed to or deteriorated in the first 24 hours 
any of the above features of severe and 
of observation after rectal or if the 
malaria 
at 
12 and 24 hours is 60% or more of the admission were to be rescued 
with intravenous 
allocated schedule in these 
1 - 4 
Patients the to 
care ventilation or haemod 
continued accord to the 
transfer to a referral for intensive 
- indicated with metabolic 
and fluid overload or urea> 50 mmoVL or who remain anuric 
after 
Discontinuation of arm 
After eleven with severe malaria had been evaluated, consensus was reached 
between investigators and sponsors, that the arm evaluating severe and 
malaria would by discontinued. This decision was based on the realisation 
that the referral in in KwaZulu Natal for transfer and intensive 
were unable to meet the standard of care 
a review of the of two patients who died 














Patients received either rectal AS 50 or Batch nos. 
or Parenteral Quinine 
Generics Ltd., South Africa) which was 
24398 and 23742 
d ihyd rochloride®, Adcock 
followed up with oral sulfadoxine - pyrimethamine Roche Products 
Quinine Ltd.) and, in with severe oral ine 
Phannacare Ltd, South 





1:10 artesunate at 0 hours followed by 3 tablets 
intramuscular if II nable to 
tolerate oral at 24 hours 
intramuscular at 0, 12 and 20 hours followed by 3 
tablets 
unable to tolerate oral 
3: 10 artesunate 
10 
at 24 hours 
PLUS 20 
intravenous quinine and then 10 mg/kg intravenous 
take oral medication; then 10 oral 8 
tr"''''trn'''''lt PLUS a stat dose of 3 tablets of sulfadoxine / 
4: 20 load dose of intravenous 
intramuscular quinine if 
load dose of 
8 until able to 
to complete 7 of 
and then 10 
intravenous until able to take oral medication; then 10 oral 
8 hourly to complete 7 days of treatment, PLUS a stat dose of 3 tablets of 
sulfadoxine / 
were administered whole, without the use of and the actual dose 
was the nearest 
Intramuscular doses of 
to the recommended dose of1 0 












with half the dose administered in each anterior thigh. Intravenous was 
administered as an infusion over 4 hours in 5% dextrose saline 0 mllkg depending on 
the fluid Patients with were to receive curative 
with "r;·,~lm Roche Ltd., South 
Method of to treatment groups. 
Patients were allocated to the different treatment arms to a textbook 
randomisation 
for 100 
in a ratio of 1 control: 4 artesunate in each arm. These were 
severe and 50 severe in 
blocks. Treatment Ci:ll:eUlorv for each patient was 
These were not 
in a sealed labelled 
by disease 
of each 
meals was not 
nn,"nc", at the time of enrolment to the The exact 
dose was documented; however the 
All measures in the 
to 
",,,,"~,ont of malaria 
were authorised. IV fluids were administered to maintain circulating intravascular volume. 
Fever was treated with and seizures were with 
IClZep,:lm and Severe anaemia was corrected with transfusion of HIV and 
B screened blood. Concomitant infections and diseases were treated 
Patients with severe and malaria were to receive the best 
available at a rural district WHO . All concomitant 
treatment was documented. Patients with severe malaria were to remain in 
until they were able to tolerate oral med ication and were 
and afebrile for at least 24 hours. Patients with severe malaria were 













Prior to d all treatment was administered by nurses, who documented time 
of administration. staff monitored of at 5, 15, 
60 and then for 6 ho urs after insertion. If the was 
in < 10 minutes, it was reinserted; if between 10 and 60 minutes a new 
was inserted. Time of re-insertion was documented. At d 
were motivated to adhere to follow up 
with 
At follow up, 
medication. 
Patients who failed initial treatment were administered: 
.. Parenteral Quinine rochlorid Adcock 







Ph armacare Ltd, South 
for treatment with rectal 
or 




a detailed and examination was , with 
the severity of the the 
assessment of extra-ocular movements, cerebellar (including heel to toe 
and fine motor coordination (includ small tablets in a narrow 
container and 
Coma Scale scores 
a line between 2 crosses 10 cm apart). 













Initial was made using the ICT® antigen test and confirmed on 
thick and thin blood films stained with reverse Field's stain and per 1000 red 
blood cells and 200 white blood 
technicians in the 





Slides were read the 
assurance of density conducted 
at the of Town of 
Mean Cell Volume White Cell Count 
a Coulter counter®. Whole blood lactate was 
measured on an automated lactate analyser Mannheim, South 
Blood gas was the IL 1640 BGE® South 
Liver function tests and tests were determined 
Analyser South Africa). Normal ranges are defined in 




lactate standard s ed the manufacturer. In after each 5 ,-,,,,nnn,,''',, were 
, an automatic re-calibration occurred with the use of internal standards. 













Patients were under care of nurses and Vital includ 
blood pressure {and Central Venous Pressure if 
and coma score were recorded at 0, 1 and 2 hours then 2 
until 48 thereafter until 96 and until 
Parasitaemia was monitored every 6h until clearance of Full Blood Count 
blood gas, blood and lactate levels were monitored every 6h until 24 
hours. Time to stand and walk unaided were monitored. 
Patients were asked to attend follow-up 7, 14 and 42 
history and includ 
smear and FBC were carried out Patients were 
they developed fever or other If 
a member of the study team visited the 
assessment. If the wa  a 
taken from members. 
definitions 
ical response: 
after entry into the A full 
as well as, 
to attend earlier if 
did not attend the 
homestead to conduct the 
the health of the was 
Standard definitions of response were used, time to reduction of 
count 50% and 90% of baseline and and clearance 
time (PCT). The latter was defined as the time to the first of at least 2 successive blood 
smears with < 1 
at 24 hours 
white cell nuclei. The fractional reduction of count 












as a percentage) was felt to be the best indicator of response to the study 
medications in view of the administration of standard antimalarial treatment to both anTIS 
at 24 hours. 
Clinical response: 
Fever clearance time was defined as the time 
remained below 37.5 DC for 2 subseq uent 
walk unaided were defined as the time from 
before the torn",:>r-:l,to re 
d stand and 
until the was first 
able to "art ............ these activities without Time to retum to per os status was defined 
as the time taken for a to return to being able to d and walk. Patients in 
the moderately severe were classified as progressed to severe and 
malaria if any of the WHO criteria of severe and 
, and / or if their parasite 12 hours after inclusion, remained above 60% 
of baseline. Coma recovery time is defined as the number of hours taken for the 
Coma Score to return to 5 after less than 5. 
evaluation 
was assessed by means of adverse event . Adverse event data was 
volunteered, with no checklist followed. An adverse event was defined as any 
symptom, of deterioration in laboratory value that or increased in 
after the administration of treatment. The adverse event fom1 in the CRF included 
of and likelihood of causal association. 
concentration measurements 
A fine gauge or IV cannula Braun Omnimed, South was 
inserted into a peripheral vein for sampling purposes. An admission of plasma 
10ml whole was obtained before study administration. At 1h, 2 h, 4 h, 














tubes and the 
in 
Methods 
randomised to 1 and 3. Whole blood was 
number and assay 
within 5 minutes of collection by centrifugation at 
for 3 min. were stored and at-70 c C in 
Concentrations of artesunate (AS) and its active metabolite d in 
were determined a and sensitive 
method with electrochemical detector in the reductive 
The assays were conducted to Good procedures 
and requirements at the Centre Sains IV''''!I'''V,",,''' 
1I/I,..,",iV,",',.., and samples were analysed by the less sensitive but reliable HPLC 
with column derivitisation and ultraviolet in the Division of Clinical 
of Town with the intention of UCT's 
in this 
assurance 
The author cond ucted sessions at the site. Data were source-verified 
the 
1 and 
with double data Data aud was """'+,.-" ..... ,,.,..-1 in October 










Chapter 3 Methods 
Statistical methods in the and determination of sample size 
This was one site in a multicentre PK/PD The number of in each 
treatment group was to be sufficient to estimate the fractional reduction of 
of the 
n::at,pn't<: would be recruited into the 
inclusion criteria the study period. 
and baseline characteristics, 
one-way and 
intended that a total of 100 
46 n']'iant" met the 
statistics were used for 
d istrib uted data were with 
distributed data the 
Mann Whiney U and Kruskal-Wallis tests. Correlation of d istrib uted data 
was the Correlation. over time in vital were 
with the Wilks lambda test. Meier Survival Curves were 
Rank test was used to the of 
variables on the fractional reduction in over time. AUC of AS 
All results were assessed and DHA were calculated WinNonLin 3.3 
at a level of with 95% confidence intervals. were conducted 












Ethical clearance was obtained from the Research and Ethics Committee of the 
of the Ethics Committee of the South African Medicines Control 
Council and the WHO Secretariat Committee on Research Involving Human 
The was conducted in accordance with the laid down in the WHO Health 
Assembly of 1975 on Ethics in Human and the Declaration of Helsinki. 
Patients were informed of the purpose of the trial and risks and benefits of the 
d rug. Patients were considered eligible for enrolment if witnessed 
informed consent was consent 
Information was to in their native with 
witnessed of the consent form. Written informed consent form was 
available in both and Zulu. 
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Between 21 March and 6 June 1998,47 no:>t,,,,nt<: were admitted to the study. Three initial 
in the study were "dummy" who were treated with ",,,,,rontor':)I 
on disease and monitored as if were enrolled in the 
These were not included in the as were not randomised. 
No accurate record was of nClt,ontc screened as many were excluded from 
the as a result of prior age < 16 years, pregnancy or 





but two were found to be 
1), and one had severe malaria 
were vnr'~"'" to meet inclusion 
use of antimalarials 
study ann for severe malaria 
was discontinued. One was randomised but then admitted recent prior use 
of an antimalarial, so was withdrawn before administration of 
thus not included in the analysis. 
features of disease 
Patients had more than one feature of 
This was 
severe 
malaria. Inability to walk was the most uent %) feature among ",':)"on're 
with severe d while clinical ice was the most 
with severe malaria. No 
(73%) 
with defining feature among 












consciousness (2 in 3 :: 12 and 
was found in 11 n::lt,,,,ntc and 
of and treatment 
On average, had been symptomatic for 3 
4.1). Patients who had been recorded as 
form did not 
rro ",·n ::11\1 in 1 0 
at the time of 
for 
this 
4 :: 8). 
on the 
were assumed 
to have been symptomatic for 6 All n::>r,,,,ntc had a history of fever. One quarter of 
had taken antimalarial and a similar had taken 
"traditional" med in Table 4.1. The more prevalent antimalarial 
use in the artesunate groups did not reach 
severe malaria Fischer's exact 
among those with """"."'or..".", 
nor among those with severe malaria 
8, Fischer's exact Over one half of 
1T"',;;t'lT'" more common in 
had taken an 
use was 




most "traditional" medicati n. 
Protocol deviations 
Protocol deviations occurred in four .... ..,.''''n.<o In three M64 and 
intravenous rescue was indicated due to a fractional 
than 60% at 12 hours. One was not rescue as the 12 hour result 
was obtained at the same time as that of 24 which showed a of less 
than 60% of baseline. A second 
rescued with oral rather than IV 
received rescue 
as this 
to receive IV The last nrntnf'.nl violation was a 
oral in error, at time 0 instead of at 24 hours. 
late, and the third was 
considered too well 












Table 4.1: Duration of ,""~,"',.,,,~ and treatment treatment group 
ALL GROUP 1 2 GROUP 3 GROUP 4 
(n :::: 
Duration of 4 






Paracetamoll 1 (2%) 0(0%) 
None 20 
Other n (%) 
None 34 
PR 7 ( 
lish PR I herbal 














Measurements of treatment 
In-patient treatment was the team of nurses and 
clinicians. Plasma 
severe malaria 
levels were obtained from all "",t,ont", enrolled. In one with 
neither artesunate nor its active metabolite were detected at any 
time (0-8 hou Pharmacokinetic results are in 5. Patients 
were ed with information to encourage them to remain 
treatment after d and were 
evaluation 
Baseline Characteristics 
There was a male 1), and were 
with follow up 
at follow up visits. 
between 16 and 
60 years. Table 4.2 summarise baseline characteristics group. Treatment 
groups 1 and 2 were for these baseline features 10), with the 
of which was in group 2 (p ::: Mann Treatment groups 3 
and 4 were for most baseline total bilirubin was 












Table 4.2: Selected baseline clinical and 








GROUP 3 GROUP 4 



























<::tn'''IIT1I''<=InTI\/ different from group of same disease """"""Hru 
Data sets 




n",n,,,,nl an Intention to treat of all who 
data set where who received 
either in error or as "rescue medication" as a result of 












All (46) receiving at least one dose of medication were included in the 
intention to treat 
outcome 
i) Fractional reduction in Parasitaemia at 24 hours 
All had a decrease in over 24 hours. The median or 
fraction of baseline at 24 hours was 0.6% in o 41%) and 
16.6% in 2 2 - 75%). The fractional reduction in was 
1 than in group 2 this 
difference was not between groups 3 and 4 This reduction reflects 
the effect of a rectal 1 0 mg I dose of artesunate in group 1 with 
intramuscular quinine administered at 0, 4, 12 and 20 hours in group 2. 
analysis of the Fractional Reduction in at 24 hours 
showed that this was decreased w~h rectal treatment (p :: 0.003), a decreased 
baseline coma score (p ::: and a decreased baseline serum albumin level 
(p ::: 0.01 Other that are "treatment 
artesunate treatment groups 1 and 3 vs. both control groups 2 and 4 p ::: and 
antimalarial treatment (p ::: 
Table 4.3: of the Fractional Reduction in at 24 hours. 
95% CI 
-1.36 - 24.33 
0.036 
0.018 -0.20 - -0.02 











Chapter 4 Therapeutic 
4.1 : 
Hnvn.nTC of Intention to Treat of the of baseline at 24 






..c .4 1tM64 









N= 27 a 5 6 
7. 
l.a",,...r,,ntn.tA and n",n_","'n~nl.",m,,... statistics 
Tables 4.4a and 4.4b summarise the and statistics of ne>rOlcrrA 
related variables. Parasite clearance times have been right censored 












Table 4.4a: Intention to Treat of the Parasite over time Treatment 
for 1 and 2 severe 
PR 1M Quinine 




















Table 4.4b: Intention to Treat of the Parasite 





(5580 - 177 593) 




682 -- 459 600) 
21 0.10 






17318) (7620 -11531 
and number of 
1T"''''fl'1I''' at 12 and 24hours 
4 
with 
reduction of absolute count 
At 12 and 24 hours the of 
absolute count from baseline was 
and between groups 3 and 4. 
0.0901 
(Log Rank 
90% reduction and clearance of 
with than 50% reduction of 












reduction of absolute count 
At 12 11 of 27 had than 90% reduction of absolute 
count from baseline in gmup 1, which is a 
Exact p ::: than that of group 2 where none of the 8 
had achieved this. At 24 22 of 27 in 
than 90% reduction of 
of p ::: 0.027 Exact 
The differences between groups 3 and 4 did not reach 
reached a 
with group 2. 
Parasite clearance at 12 and 24 hours 
The of 
exact 
achieving clearance at 12 hours did not differ 
1 vs 2 and 3 vs 4. 
clearance was 
p ::: 0 This difference was not 
at 24 hours the 
in 
between 
3 and 4 at 24 hours. 
Parasite Clearance Time 
Parasite clearanc  time was defined as the time to the first of two negative thick 




3 and 4 (p::: 0.0901). 
with the Rank Test. The peT was 
rectal artesunate 
this did not achieve 













4.2: Meier Survival Curves of with 
severe malaria treatment group to Treat 
p 
2 -1M ON I 












Table 4.5: Intention to Treat of the number) of "-:>",an"" with 
90% reduction and clearance of from baseline at 12 and 24 hours 
Table 4,5a: 1 and 2-
Number of 
:::,50% reduction at 12h 
reduction at 
Cleared at 12h 
reduction at 24h 
at 24h 
Table 4.5b: 3 and 4 
Number of 
reduction at 12h 
reduction at 12h 
Cleared at 12h 
>50% reduction at 24h 
severe malaria 
GROUP 1 













different from group 
Severe malaria 
GROUP 3 GROUP 4 
N=5 N=6 
-----
40% 17% (1) 
0 0 
0 0 






















Fever clearance times 
Defervescence occurred with the four treatment 
difference in reduction in fever in 24 hours 
p=O.38), nor between groups 3 and 4 (t test p ::: 
hours did not differ 
between 3 and 
between 
4 (t test p :::: 
There was no 
between groups 1 and 2 (t test 
Mean at 24 
2 (t test p ::: nor 
there was no difference in the 
number of with fever> 37.5°C at 24 hours between groups 1 and 2 
exact test p ::: 0.41), nor between groups 3 and 4 exact test p ::: 1.0). 
at 24 hours was not recorded for 1 in 1. Fever 
clearance time was 





more in 2 to Rank 
between group 3 and 4 Rank test p ::: 
and 824 - Group 3) were excluded from the 
on admission. 
of 
Table 4.6: Intention to Treat of the effect of treatment on fever related 
as Mean, 95% Confidence Intervals unless 















in are also described in '''''''''''"6: 
The effects of treatment over time on lactate, 
Base Bilirubin and Calcium were tested (at 
12 hours, 24 hours, discharge and on 7, 14 and These did 
not over and Iy reflected a normalisation of 
values. 
A random effects model showed no 0) effects of time or 
treatment on haematocrit in with severe, or severe, malaria. 
There was no between treatment and time. there was a significant 
decrease in haematocrit in with severe malaria (p=0.006) but not 
severe malaria 8) over the initial 24 hours. Treatment groups did not differ 
the decrease tended to be more in with severe 
malaria treated with rectal artesunate and IV quinine 3) with thise 
treated with IV quinine alone 
4.3: Intention to Tr at of the Mean haematocrit at O. 24 
7,14 and treatment group (Group 1: AS / 2 1M Quinine I 













The decrease in serum lactate over time was not in with either 
severe or severe malaria. As "'V""'f"t",n serum lactate was 
in with severe malaria 






One 1 ) mild at24 which 
not confirmed on evaluation resulted in the withd rawn and 
treated with This clinical jaundice had resolved day 3. 
Platelets increased over time in all with severe malaria 
(p ::: 0.001), as would be in patients effective antimalarial Trp::InlnPllT 
but not in with severe malaria (p=0.678). This effect did not differ between 
treatment groups 
and 




.39 in severe and 0.948 in severe 
Rate were monitored over time. Across all groups there was 
overall decrease in Pulse Rate Lambda p ::: 0.01), and 
Lambda p ::: 0.008) over time. There was a overall 
Blood Pressure Lambda p ::: 0 over time. The differences 
1 and 2 and between 3 and 4 did not reach at any 













No deaths occurred in 1 and 2. One died in 3, and 2 
and died in 4. Details of each death are 6. The 
difference in the Case Rates between 3 (20%) and 4 was 
not exact test p = 1.0). All 3 deaths were considered consistent with 
death from severe and malaria. 
to severe and malaria 
No in 1 and 2 WHO for the 
although one 1) 
at 24 which was not confirmed on 
bilirubin. This ice had resolved by 3. Another 
lactate was recorded as 5.9 mmollL at 24 recovered 
medication. 
of severe and 
mild 
evaluation of total 
1) whose 
without rescue 
Time to retum to per os status 
Once were able to drink and were considered as". The 
differences in time to per as status between Rank test p ::: 0.5521), 
and between groups 3 and 4 Rank test p = were not significant. All 
with moderately severe malaria received oral administration of SP at 24 hours. Time to 
retum to per as status was ht censored in 4 (1 in group 3, 3 in 4), who 
died or were transferred to a referral for intensive care without to a 
os" status. 
------------












Final treatment outcome 
No were found to be P. /.-:lIIA'''o// smear between 7 and day 
this cannot be excluded in lost to follow up. Three were lost to 
follow up M85 and 2 of which were in and 1 in Group 2. peR 
samples were on 1 of 3 follow up visits in 3 (Mig, M64); these 
were smear and peR on both of the other follow up visits. 
Seven had positive peR smears, very low 
or peR was used to differentiate recrudescence 
from re-infection. peR SU(lOE:stEld recrudescence in 5 1, 2/7 in 
(1/25 in 2 and 1/4 in and non-recrudescence in 2 further 
1,114 in 
which 
and SP was the 
treatment outcome is most 
Two n",t,pn·tc: 17 and 
no peR was obtained at 3 of 3 
Since all patients had received at least 2 antimalarial 
administered in curative final 
to reflect resistance to SP. 
health care clinic on 
and were treated with sulfadoxine 1 after 
10 and 
leT 
these Since smears and peR before and after re-treatment were 
be considered false leT tests. One (M47) received rescue therapy 
with on d7, in addition to AS and SP in error, identification of 
this was found peR on 14 and 42 to have a recrudescent 
infection. 
66 
University of Cape Town
4 
Table 4.7: Intention to Treat of the Smear and peR results of with evidence of summary of treatment 
administered and of final treatment outcome NK not 
+ - Artesunate (1); PO SP (1) 












t-nU!-'lrt::v Data Set 
Of the 46 initially evaluable was withdrawn between 0-12hours (M50, 1) 
as a result of administration of sulfadoxine I in error. A further 5 
''''':It,emtc were withdrawn between 12 and 24 hours as a result of administration of rescue 
therapy for than 60% of baseline at 12 hours 1 : 2: M02, 
M62 and Between 24 and 36 hours a further 
of mild confirmed 
treatment with additional (All 46 
4.4: Patient 
, Ev:iuablea' 24 hours 
, (0"25) 
I ATror~~r\l data 
Palienls S"eened 
(n 0 53) 
was withdrawn due to the 
bilirubin and 


















Primary endpoint: Fractional reduction in Parasitaemia at 24 hours 
All had a decrease in 
proportion or fraction of baseline 
0- and 31% in 
was 
over 24 hours. The median 
at 24 hours was 0.6% in 
3 - The fractional reduction in 
in Group 1 than in group 2 
p= This reduction reflects the effect of a rectal 10 mg I dose of 
artesunate in group 1 with intramuscular administered at 0,4, 
12 and 20 hours in group 2. This difference in fractional reduction in 
at 24 hours was not between groups 3 5 and 4 
- Mann p;:;:; 0.273. 
and non statistics 
Table 4.8 summarises the and r<ln,,,,t.·,,... statistics of 











Table 4.8: Per of Parasite over time by Treatment 































and number of with 90% reduction and clearance of 
at 12 and 24hours 
reduction of absolute count 
At 12 and 24 hours the n'n,nnrllnn of with nn::.,:>tor than 50% reduction of 
absolute count from baseline was 
exact p 0.001 and p == 0.015 in 
2. The 
12 hours and 



















11 of 26 than 90% reduction of absolute 
count from baseline in group 1, which is a 
Exact p = than that of group 2 where none of the 8 
had achieved 90% reduction. At 24 22 of 25 in 
than 90% reduction of count from 
with this reduction in 50 0A, of those in 
which 
2 (p = 0.127 
Parasite Clearance Time 
The mean clearance time overall was 55 hours 6 censored 
The PCT by treatment group were summarised 
Meier Survival and with the Rank Test. The difference in 
PCT between 1 and 2 (p = and between 3 and 4 (p = 












Table 4.9: Per of the of n:;n,pnf';: with 50%, 
90%, reduction and clearance of n':lr':l"'"'':l from baseline at 12 and 24 hours 
9a: 1 and 2 
PRAS 1M QUININE SIGNIFICANCE 
0.001 * 
42%(11)* o 0.034* 
Cleared at 12h 8% o 1.0 
100% 50% 0.015* 
50% 0.127 
44% o 0.268 
different from group 
Table 4.9b: 3 and 4 
Number of PR AS IV IV QUININE SIGNIFICANCE 
QUININE 
11-------------·--<..·----------'----·--·---"---- ·---....,1 
17% (1) 0.545 
o 
I~~--~~~----+~------+~----------I~-------~I 














Fever Clearance (Table 4.10) 
Defervescence occurred with the four treatment n>f'I,m<>n There was no 
difference in reduction in fever by 24 hours (delta between groups 1 and 2 , nor 
between groups 3 and 4. There was no difference in the number of with fever> 
37.5"C at 24 between groups 1 and 2 exact p ::: 
and 4 
2 
exact p ::: 1 Fever clearance time was 
to 1 
and 4 (Log Rank test p ::: 
were excluded from the 
Rank test p ::: 
Two 




clearance times were classified as 
without defervescence. 
censored in 
nor between groups 3 
more in 
between group 3 
1 and S24 -






















No deaths occurred in 
of the 
37.4 
1 and 2. One 







and died in 4. Details of each death are 
Rates behNeen 
exact test p 





LJI"£""'''''':''',l'\n to severe and COfn/J/lcarea malaria 
No n:.u,p""" in 1 and 2 .,. .. ·" ... "'n~'" WHO criteria the of severe and 
1) mild 
which was not evaluation. This 
had resolved 3. Another 
5.9 at 24 recovered 
1) whose lactate was recorded as 











Time to return to per os status 
Once were able to eat, drink and were considered as", Time to 
return to per as status was censored in 4 {1 in group 3, 3 in who 
died or were transferred to a referral h",'nit",1 to as" status, The 
differences between Rank test p ::: and between groups 3 












5: Pharmacokinetics of artesunate and 
received the closest dose to 1 AS 200 and 500 
Extent of 
All 
mg The mean artesunate dose administered in with 
severe malaria 1) was 9.95 CI: 9.86-1 and in severe malaria 




were determined for artesunate and its active 
as well as for the sum of both artesunate and 
dihydroartemisinin. As AS is rapidly and rolysed to DHA 
and/or tissue AS is sometimes considered a for DHA. 
Since artemisinins are membrane bound, a validated for 
levels at the site of action (within the has not been established and our results 
reflect levels. 
Samples were analysed for AS and DHA HPLC eq with an electro-chemical 
considered the reference ue for studies as 
this has and 
. The 
were 
below the detectable limit in this 
determination of 
than the HPLC-UV detection or 
ucibility of this assay is reported in Appendix 4. All 
to GLP Levels 
were assumed to be zero for the 












assay was 1 
detectable limit 
There were 90/192 AS levels and 134/192 DHA levels above the 
treatment. Nine AS levels were classified as as the 
. All AS and DHA levels prior to exposure were zero. Levels as "out 
of were included in this as these made up a substantial of the 
results AS concentrations and 231148 DHA concentrations above the level of 
In the 
administration. In four 
of AS and DHA were detectable 1 hour after 
DHA was detected. In one 
neither AS or DHA were detected at any time point 
with severe 
AS and DHA 
plasma concentrations did not appear to decline with time in one and six 
In children, both artesunate and d roartemisinin were cleared before 8 . As this 
study in children was the rectal artesunate PK data available when our was 
, we assumed that these kinetics would also be seen in adults. 
AS and DHA 
adults when 
concentrations declined more slowly over time in our non immune 
with children with severe malaria. our 
time was limited to 8 hours. Elimination half life and 
could not be calculated for AS or DHA due to insufficient data points on the elimination 
curve. 
was calculated 
as the limited data 
a 
the use of a 
model in WinNonLin4.0 in this 
model. A one 
model with first order appearance and elimination kinetics a time was 
observed to best fit the d roartemisinin data in studies with more 













Table 5.1 and 
severe 




5.1a-c summarise the observed plasma levels for patients with 
1) and severe malaria 
levels of artesunate and roartemisinin, and 











Chapter 5 Pharmacoki netics 
Figures 5.1 summarise the observed plasma levels of artesunate and dihydroartemisinin, 
separately and combined, in moderately severe (Group 1) and severe malaria (Group 3). 
Figure 5_1a: Plasma concentrations of artesunate over time 
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Figure 5_1 b: Plasma concentrations of dihydroartemisinin over time 
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Chapter 5 Pharmacokinetics 
Figure 5.1 b: Plasma concentrations of artesunate plus dihydroartemisinin over time 
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Marked inter-individual variability was noted in this study (100% coefficient of variation for 
both AUC and Cmax). The Cmax (p=O.008) and AUC (Figures 5.1a-c) of both AS and of 
DHA, separately and combined, were significantly higher in patients with moderately 
severe malaria when compared with severe malaria (Table 5.2). This significance of the 
difference for combined AS plus DHA was preserved whether AUC all (p=0.006) or AUC 
last (p=0.008) were compared. 
Table 5.2: Pharmacokinetic parameters of Artesunate plus DHA by disease severity 
[median and interquartile range (lOR)] 
Moderately Severe (Group 1) Severe (Group 3) 
N Median (lOR, N Median (lOR, p-value (Mann 
Whitney U) 
CMAX 27 773.4 (429.0-1792.0) 5 196.€ (42.6-378.7) 0.008 
TLAST 27 8 (6-8) 5 6 (2-8) 0.241 
CLAST 27 105.6 (53.2-787.2) 5 118.C (42.6-182.2) 0.511 
AUCLAST 27 3398.3 (1422.1-8479.1) 5 5939 (218.9-1271.7) 0.008 
AUCALL 27 3457.1 (1509.6-8479.1 ) 5 758.7 (218.9-1330.7) 0.006 











Chapter 5 Pharmacokinetics 
The negative correlation between fractional reduction in parasitaemia at 24 hours and 
AUC all (Spearman correlation p==0.13), AUC last (Spearman correlation p=0.133) or 
Cmax (Spearman correlation p=0.18), did not reach significance (Figure 5.2). 
Figure 5.2: Scatter graph of AUCall of AS plus DHA with Percentage of baseline 
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Chapter 5 Pharmacokinetics 
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Chapter 6 Tolerability 
CHAPTER 6: 
Extent of exposure 
Thirty two patients received AS (27 moderately severe and 5 severe malaria) according 
to randomisation, while fourteen received quinine (8 moderately severe and 6 severe 
malaria). Demographics of these patients are described under Chapter 4: Therapeutic 
efficacy. Patients received the closest possible dose to 10mg/kg AS rectally, using 200 
and 500 mg suppositories. The mean dose in Group 1 was 9.95 mg/kg (CI: 9.86-10.05) 
and in Group 3 was 10.11 (CI: 9.63-10.58). Quinine was administered strictly according 
to body weight, with 20 mg/kg administered initially as a loading dose, followed by 10 
mg/kg at 4 hours, 12 hours and then 8 hourly until able to tolerate oral medication. 
Definitions 
Adverse event (AE): any untoward medical occurrence (symptom, sign or special 
investigation) in a subject administered pharmaceutical product and which does not 
necessarily have a causal relationship with this treatment. 
Adverse drug reaction (ADR): all noxious and unintended responses to a medicinal 
product (a causal relationship is at least a reasonable possibility, i.e. cannot be ruled out) 
related to any dose. 
Serious ady~rse !2.vent (SAE): An adverse event that is fatal or life-threatening, results in 
persistent or significant disabilitylincapacity, requires inpatient hospitalisation or 
prolongation of existing hospitalisation, is a congenital anomaly/birth defect, or is an 











Chapter 6 Tolerability 
Life-threateni'!]l}: Immediate risk of death from the adverse event as it occurred, in the 
view of the investigator/reporter. It does not refer to an adverse event that, had it 
occurred in a more severe form, might have caused death. 
Disability: A substantial disruption of a person's ability to conduct normal life functions. 
Important medical event: Any adverse event that may not be immediately life-threatening 
or result in death or hospitalisation but required medical intervention in order to prevent a 
serious outcome. The medical intervention can occur in any setting (e.g, emergency 
room, home, etc). 
Frequency of Adverse Events 
Sixteen patients (59°/,,) with moderately severe malaria in Group 1 experienced one or 
more adverse events, compared with seven patients (87.5%) in Group 2; this difference 
in frequency was not significant (Fisher's Exact Test p ;:;;; 0.145). 
Adverse events were grouped according to the WHO Adverse Reaction Dictionary 
Preferred terms\ as summarised in Table 6.1. Gastro-intestinal, followed by respiratory 
adverse events were the most frequent event in both Groups 1 and 2. Three patients in 
Group 2 developed reactions at the site of 1M quinine injection. None of the adverse 
events in the patients with moderately severe malaria were assessed as being "serious". 
A total of 7 adverse events were described in 5 patients in Group 3 and 21 events in 6 
patients in Group 4. Gastro-intestinal adverse events were the most frequent in both 
1 World health Organisation Collaborating Centre for Intemational Drug Monitoring, Uppsala, 











Chapter 6 Tolerability 
Groups 3 and 4.The frequency of serious events was not significantly different between 
Group 3 and Group 4 (Fisher's Exact test p = 1.0). 
Table 6.1: Frequency of Adverse Event Preferred Terms by Treatment Group 
Table 6.1 a: Patients with MOD ERATEL Y SEVERE malaria 
------------.-.--~-... --.-.. --.. -··----·~--··------···--··--___r:_:-·:_··::,_=___:_--·c-·~-----T------, 
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Chapter 6 Tolerability 
Deaths and other serious adverse events 
There were no deaths or serious adverse events among the study patients with 
moderately severe malaria. Three patients (1 in Group 3, 2 in Group 4), all whom 
presented with severe and complicated malaria, died while on study. Mosvold hospital is 
a rural district hospital without facilities for intensive care, ventilation or dialysis. During 
the planning of this study it was agreed by the staff of both Mosvold and the referral 
hospitals that ambulance services and referral systems were adequate for transferring 
patients requiring these facilities. An international review panel however decided to stop 
the severe arm of this study on May 18 1998 following substantial problems experienced 
in these referral systems, which may have contributed to the death of both patients 
transferred to a referral hospital for ICU management. These problems are clearly not 
specific to this study but reflect the challenges of treating patients with severe malaria in 
this region. The panel agreed that all deaths appeared to be attributable to malaria. 
One death occurred among 5 patients in Group 3, the study patients with severe malaria 
who were treated with both rectal artesunate and intravenous quinine. This patient (S24) 
was a 52 year-Old woman who presented to hospital with severe malaria 8 days after the 
onset of symptoms. She had apparently been treated at a nearby clinic with oral SP two 
days prior to admission, despite already being prostrated and confused. On admission 
she was found to be prostrate, confused (GCS 14/15), and had hepatosplenomegaly and 
a lobar pneumonia. Within 24 hours her level of consciousness deteriorated (GCS 9/15) 
and she developed metabolic acidosis and renal failure, despite treatment per protocol 
with intravenous quinine, a single rectal dose of artesunate and cefuroxime (750 mg 8 
hourly). Her parasite density decreased by 95% within 24 hours. She was withdrawn from 
the study 25 hours after admission so that she could be referred to the provincial 
academic hospital intensive care unit for haemodialysis and ventilation. She appeared to 
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hour delay before she was admitted to the medical ward (not ICU as arranged) and a 
further 2-hour delay before administration of quinine was documented (total 19 hour 
quinine dosage interval). Haemodialysis was refused as she was haemodynamically 
unstable by the time of referral for heamodialysis. After her second cardio-respiratory 
arrest she was finally referred to the ICU (despite telephonic ICU acceptance of referral), 
where she arrested again soon after arrival and this resuscitation was unsuccessful. She 
died 61 hours after inclusion in the study, and 36 hours after withdrawal from the study 
for referral to the provincial academic hospital. Post mortem examination showed that her 
lungs were congested and voluminous with black oedema fluid; her kidneys, heart, liver 
and brain were very pale; her spleen was very dark red black and diffluent No signs of 
meningitis or ATN. On the basis of these findings the pathologist confirmed that this 
death appeared to be attributable to severe malaria. 
Two deaths occurred among six patients in Group 4, the study patients with severe 
malaria who were treated with intravenous quinine only. The one death in this group 
occurred in a 29-year old man who was referred for dialysis 24 hours after study 
inclusion, after consultation with the ICU physician at the regional referral hospital. 
Unfortunately he was retumed 11 hours later still anuric with signs of fluid overload, a 
right sided pneumonia and a GCS of 4/15. ICU admission and peritoneal dialysis had 
been refused on the assumption of his poor prognosis based on his HIV positive status 
(indicated by a single rapid diagnostic card test done at the referral hospital) and 
decreased level of consciousness. He died 6 days after study enrolment despite per 
protocol treatment of his severe malaria, careful management of fluid balance (including 
central venous pressure monitoring) and appropriate treatment of his pneumonia (initially 
cefotaxime, then adding gentamycin and cloxacillin and later rifampicin, isoniazid, 
pyrazinamide and ethambutol). Relatives refused permission for autopsy or lung biopsy. 
The other patient in Group 4 who died (S31) was a 49 year old man who presented with 
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day 6 after developing ARDS despite careful management of fluid balance (including 
central venous pressure monitoring) and appropriate treatment of a possible pneumonia 
(initially cefotaxime, then adding gentamycin and cloxacillin). 
Clinical and laboratory evaluations 
The effects of treatment over time on HCT, WCC, platelets, glucose, lactate, pH, HC03, 
Base deficit, Sodium, Potassium, Urea, Creatinine, Bilirubin and Calcium were tested (at 
baseline, 12 hours, 24 hours, discharge and on days 7, 14 and 42). These generally did 
not change significantly over time. 
A random effects regression model showed no significant (p>0.10) effects of time or 
treatment on haematocrit overall, in patients with moderately severe, or severe, malaria. 
There was no interaction between treatment and time. However, there was a significant 
decrease in haematocrit in patients with moderately severe malaria (p:::O.006) but not 
severe malaria (p=0.218) over the initial 24 hours. Treatment groups did not differ 
significantly, although the decrease tended to be more rapid in patients with severe 
malaria treated with rectal artesunate and IV quinine (Group 3) compared with those 
treated with IV quinine alone (p=0.070). 
Figure 6.1: l\I1ean haematocrit at O. 24 hours, discharge, day 7, 14 and 42) by treatment 
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The decrease in serum lactate over time was not significant, in patients with either 
moderately severe or severe malaria. As expected, serum lactate was significantly 
higher in patients with severe malaria (p=O.002). One patient (M96, Group 1) whose 
lactate was recorded as 5.9 mmollL at 24 hours, recovered uneventfully without rescue 
medication. 
One patient (M53 Group 1) developed mild jaundice clinically at 24 hours, which although 
not confirmed on laboratory evaluation, resulted in the patient being withdrawn and 
treated with quinine. This clinical jaundice had resolved by day 3. 
Platelets increased significantly over time in all patients with moderately severe malaria 
(p ::: 0.001), as would be expected in patients receiving effective antimalarial treatment, 
but not in patients with severe malaria (p=0.678). This effect did not differ between 
treatment groups (p=0.39 in moderately severe and 0.948 in severe malaria). 
Vital signs 
Pulse, SBP, and Respiratory Rate were monitored over time. Across all groups there was 
a statistically significant overall decrease in Pulse Rate (Wilks Lambda p = 0.01), and 
Respiratory Rate (Wilks Lambda p =: 0.008) over time. There was a significant overall 
increase in Systolic Blood Pressure (Wilks Lambda p =: 0.004), over time. The differences 
between Groups 1 and 2 and between Groups 3 and 4 did not reach significance at any 
time point. As expected with effective treatment, these showed a normalisation of values. 
Neurological Evaluation 
Patients were assessed for neurological abnormalities (as defined in Chapter 3: Methods) 
by treatment group at baseline, discharge and day 7, 14 and 42. There was no 
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Changes in clinical state following treatment may potentially bias the rigour with which the 
neurological evaluation could be conducted at admission. Dysdiadochokinesis was only 
included in the neurological evaluation conducted at admission, and (in error) not 
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Chapter 7: Discussion offindings and limitations of study 
The clinical and parasitological responses observed in non-immune adults following a 
single dose of rectal artesunate support its use as an early intervention to provide initial 
antimalarial therapy in patients with potentially life threatening malaria, particularly for 
those who do not have ready access to effective parenteral treatment. These findings 
suggest that such treatment would provide useful therapy to cover the period before the 
patient could reach a health care facility equipped to provide parenteral treatment. 
This and previous studies15 indicate that in patients treated with parenteral quinine for P 
fa/ciparum malaria, the density of peripheral parasitaemia seldom falls below 60% of 
baseline by 12 hours, or below 10% of baseline by 24 hours. In the present study, 
parasitaemia fell below these levels in 26 of 27 adults with moderately severe malaria 
and 3 of 5 patients with severe malaria treated with artesunate. This rate of reduction in 
the density of parasitaemia is characteristic of the action of artemisinin derivatives, and 
suggests that artesunate was responsible for the antiparasitic effect observed. In 25 of 27 
adults this rate of reduction occurred in the absence of any antimalarial treatment 
administered during the study other than artesunate. It appears unlikely that the more 
prevalent prior use of antimalarial treatment in the artesunate groups might have 
contributed substantially to the observed differences between treatment groups. The 
differences in prior antimalarial use did not achieve sign~icance with Fischers exact test 
(p::O.15) nor logistic regression regression analysis (p=O.09). Primaquine is considered 
effective monotherapy for Plasmodium falciparum1, and chloroquine resistance was 
prevalent (47% in 1997) at the study site (Brian Sharp, unpublished report). Although 
sulfadoxine-pyrimethamine resistance was rapidly increasing from 18% observed in 1997 
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enhanced the efficacy of SP by increasing drug concentrations given its long elimination 
half-life. 
The sampling schedule which precluded the calculation of elimination half-life and of 
AUCo_ais a major limitation of this study. Inclusion of this data in a multi-centre population 
pharmacokinetic evaluation will facilitate further exploration of the pharmacokinetics of 
rectally administered artesunate. In all 27 adults with moderately severe malaria, and in 
four of five adults with severe malaria, at least one blood sample collected within the 8 
hours after treatment contained detectable levels of artesunate or its active metabolite, 
d ihyd roartem isin in. 
Of 27 patients with moderately severe malaria, 26 had parasitological evidence of 
adequate absorption of artesunate, while only three of five patients with severe malaria 
demonstrated the rate of reduction of parasitaemia associated with artemisinins. 
Measurable d rug exposure could not predict parasitological or clinical response to 
treatment. There was no significant association between fractional reduction in 
parasitaemia at 24 hours and AUC (p=O.13), or Cmax (p=0.18) in this small cohort. 
Marked inter-individual variability was noted (100% coefficient of variation for both AUC 
and Cmax), which was not explained by inter-individual differences in disease severity 
alone. Studies to date have generally achieved plasma concentrations in excess of those 
required for maximum antimalarial activity, thus precluding the description of this 
concentration-effect relationship3,4,5 This may suggest that therapeutic levels of these 
potent artemisinin derivatives approach the minimum detectable level of the HPLC 
artesunate and dihydroartemisinin assay. Additional explanations for the lack of 
correlation between pharmacokinetic parameters and parasitological effect could be that 
a rapid exposure to artesunate and/or dihydroartemisinin is sufficient for a 
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be identified. The clinical relevance of plasma levels of these agents, whose site of action 
is intra-erythrocytic, remains to be confirmed once a whole blood assay is developed. 
This study aimed to provide evidence in support of the use of artesunate suppositories for 
the initial treatment of patients with potentially life-threatening malaria, in rural settings 
where injections cannot be safely administered. Because the use of artesunate 
suppositories had not yet been established in this context, we studied only patients 
presenting to a reasonably well-equipped dedicated ward in a rural district hospital where 
close observations could be made. Malaria diagnosis was confirmed by microscopy in 
our study and this may not be feasible in many of the communities requiring access to 
rectal artesunate. Thus the outcomes observed in this study may be associated with the 
monitoring, nursing and supportive management provided to patients with confirmed 
malaria and may not be generalisable to facilities where these are not available. 
Many individuals with life-threatening malaria for whom rectal artesunate has been 
developed suffer from severe malaria, including coma, severe acidosis, severe anaemia 
and impairments of pulmonary and renal function. It is therefore of concern that the 
CMAX and AUC of both AS and of DHA, separately or combined, were significantly lower 
in patients with severe malaria when compared with those with moderately severe 
malaria. Although findings in such a small sample should be interpreted with caution, our 
results may suggest that the rectal absorption of AS is reduced or delayed by increased 
disease severity. These differences may (in part, at least) be accounted for by: 
• decreased gastro-intestinal perfusion with increased disease severity, thus 
decreasing or delaying the absorption of rectal artesunate; 
• a possible drug interaction with intravenous quinine, although no evidence of 
such an interaction was found; or 
• an increased concentration of artesunate and dihydroartemisinin within the 
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preferentially accumulated in parasitized red blood cellsu. Parasite density 
generally increases in patients with more severe disease. This may result in a 
decrease in plasma but not RBC levels of AS and/or DHA, although an 
equilibrium between plasma and RBC levels might have been expected. 
However, there was no correlation between AUC or Cmax with baseline density 
of peripheral parasitaemia. Peripheral parasite density, however, may not reflect 
total parasite load since parasitised red blood cells are more frequently 
sequestered in severe disease. 
The discontinuation of the severe arm of this study following unexpected but substantial 
concems regarding the public sector referral system in northern KwaZulu Natal, resulting 
in limiting this sample to only eleven patients, is a major limitation of this study. The 
challenges of managing severe malaria at this rural district hospital, and even at the 
referral, hospital emphasise the critical importance of preventing the progression of 
moderately severe malaria. Studies to confinn the adequacy of absorption and 
parasITological and clinical efficacy of rectal artesunate in patients with severe malaria are 
needed. 
Fever clearance times have been shown to be shorter in artemisinin-treated than quinine-
treated patients in most studies. However, in patients with moderately severe malaria in 
this study fever clearance was significantly slower in the artesunate than the quinine 
group. Rapid fever clearance could be a danger if patients believe that further treatment 
is not needed, as single-dose treatment with any artemisinin is insufficient to cure 
malaria. Deployment of rectal artesunate for severe malaria in peripheral units should be 
accompanied by adequate explanation to patients or guardians that the initial therapy on 
its own is not sufficient, even if the patient appears to get better. They must understand 
that further effective curative treatment at a referral centre is necessary. In our study, 
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treatment failures (recrudescences) as no parasites were detected microscopically to 
differentiate asexual parasitaemia from gametocytaemia. This rate is lower than the 18% 
parasitological SP failure rate reported for this study site in 1997 (Brian Sharp, 
unpublished report). 
In this study, the final treatment outcome depended on the efficacy of SP, as this was the 
only treatment given at a curative dose. It was possible to follow up the majority (91 %) of 
patients for 42 days and to use PCR to differentiate recrudescence from re-infection. 
Treatment failed in 8% of patients in the artesunate group compared with 29% in the 
quinine group (p>0.10). Initial artesunate achieved the desired effect of improving the 
patient's clinical condition and reducing parasitaemia. The appropriate follow-on 
treatment to effect a cure is dependent upon local pattems of P falciparum drug 
resistance. 
Concerns that the use of rectal artesunate for life-threatening disease would increase the 
development or spread of artemisinin-resistant P falciparum are unlikely to be justified. 
By ensuring this rapid reduction of parasite biomass, administration of artesunate 
suppositories is likely to reduce the probability of the presence of a parasite resistant to 
SP (or alternative curative therapies) at 24 hours? 
tf this emergency treatment is deployed in peripheral areas, staff, patients and parents 
must be informed of the need to observe for expulsion of suppositories: two of 27 adults 
(7%) in this expelled suppositories, usually within the first fifteen minutes. Reinserted 
suppositories were usually retained. 
Patients and their relatives in South Africa, readily accepted the use of rectal therapy in 
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polish and toothpaste) indicates the acceptability of the rectal route of administration in 
this community. 
Artesunate was generally well tolerated at 10 mg/kg administered rectally in the small 
cohort studied. The frequency of serious adverse events, and of adverse events overall 
did not differ significantly between artesunate and control study groups. Artemisinin 
drugs have been used extensively, especially in SE Asia, for the treatment of P 
falciparum malaria, with very little evidence of toxicitl. Careful clinical neurological 
examination in this and previous studies has failed to detect any signs of neurotoxicity, 
which is consistent with other findings in human studies of artesunate9 . Concerns about 
potential neurotoxicity stem from reports of an unusual pattern of damage to the 
brainstem nuclei induced by high dose parenteral arternether and arteether in animal 
studies, and a prolonged coma time observed when artemether was compared with 
quinine in the treatment of cerebral malaria 1o,11, AlthoUgh these findings remain a cause 
for concern, a meta-analysis found no increased risk of prolonged coma in the artemisinin 
derivative treated groupS12. The one or two doses of the water soluble artesuntate 
administered rectally for initial treatment of moderately severe disease are even less 
likely to have toxic effects, and no such effects were observed in the present study. 
While artemisinin derivatives have been widely used in Southeast Asia, this is not yet the 
case in Africa where they have a potentially important role, both in combination 
therapies13 and as prompt treatment of potentially life threatening malaria. Our results 
suggest that at least in non-immune adults with malaria of moderate severity, and 
possibly in those with severe malaria, artesunate given by suppository is absorbed to a 
beneficial extent in the majority of individuals. Artesunate suppositories can be safely 
administered in minimally equipped health care facilities, and even homes, and result in a 
more rapid reduction in parasitaemia than is seen with parenteral quinine. Provided that 
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care facility able to provide parenteral treatment and appropriate supportive 
management, this intervention has the potential to reduce malaria related morbidity and 
mortality in those rural areas in Africa which bear the heaviest malaria burden. 
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8: Conclusions and implications for future 
The findings of this study suggest that a single rectal dose of artesunate is expected to be a 
useful option for initial treatment of patients with moderately severe malaria who are unable to 
tolerate oral medication, particularly where parenteral treatment is not readily available. The 
benefits of rapidly reducing parasite density and maintaining clinical stability while patients are 
being transferred to a facility where they have access to parenteral treatment and supportive 
management, need to be confirmed within the normal context of use. Patients with malaria 
who do not have access to parenteral treatment are unlikely to have access to the definitive 
diagnosis, monitoring or supportive management received by patients in this study. 
Although rectal artesunate appeared well tolerated in this study, ongoing pharmacovigilance 
is required, particularly regarding potential embryo-, haematological- and neuro-toxicity. The 
effect of increased disease severity, and co-morbidity (particularly with HIV/AIDS, malnutrition 
and tuberculosis) on the frequency and nature f adverse reactions needs to be determined. 
Given the prevalence of the use of concomitant treatment (both western and traditional 
medication), and the necessity to complete treatment with another effective antimalarial, it is 
important to evaluate in vivo, as well as in vitro, the potential for drug interactions with 
commonly used antimalarials (particularly quinine, as this is currently the treatment most 
widely used in severe malaria, and those used in artemisinin-based combination therapies) as 
well as for interactions with other essential drugs which have a similar adverse effect profile. 
The limited data obtained from only five patients with severe falciparum malaria in this study 
raise concerns as to whether rectal artesunate is adequately absorbed in this group. As the 
target population for whom rectal artesunate has been developed includes those with severe 
malaria, it is essential that studies are conducted to establish the pharmacokinetic, 
parasitological and clinical evidence of benefit of a single administration of a rectal artesunate 
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Efficacy of rectal artesunate compared with parenteral quinine in 
initial treatment of moderately severe malaria in African children 
and adults: a randomised study 
1\ I Barnes, J Mwenechanya, M Tembo, H Mcllleron, P I Fall), I Ribeiro, r Little, M Gomes, M E Molyneux 
Summary 
Background Many patients with malaria of increasing 
severity callnot take medicines orally, and delay in injectable 
treatment can be fatal. We aimed to assess the reliability of 
absorption, antimalarial efficacy, and tolerability of a single 
rectal dose of artesunate in the initial management of 
moderately severe falciparum malaria. 
Methods 109 children and 35 adults were randomly 
assigned to rectal artesunate (single dose of about 
j 0 rng/kg) or parenteral quinine treatment (10 mg/ kg at 0, 
4, and 1.2 h). The primary endpoint was the proportion of 
patients with periptleral asexual parasitaemia of less than 
60% of tilat at baseline after 12 h. Secondary endpoints 
wele clinical response and concentrations of drug in plasma. 
Analysis was by intention-to-treat. 
FindIngs All artesunate-treated patients had 
pharmacodynamic or pharmacokinetic evidence of adequate 
drug absorption. 80 (92'%) of 87 artesunate-treated children 
had a 12 h parasite density lower than 60% of baseline, 
compared witll three of 22 (14%) receiving quinine (relative 
risk 0·09 [95% CI 0·04-0·19]; p<0,0001). In adults, para-
sitaemia at 1.2 h was lower than 60% of baseline in 26 (96%) 
of 27 receiving artesunate, compared with three (38%) of 
eight receiving quinine (relative risk 0,06 [0·01-0-44]; 
p=0·00(9). These differences were greater at 24 h. Clinical 
response was equivalent with rectal artesunate and 
parenteral quinine. 
InterpretatIon A single rectal dose of arteSlJnate is 
associated wittl rapid reeluction in parasite density in adults 
and children with moderately severe malaria, within the initial 
24 11 of treatment. This option is usefu I for initiation of 
treatment in patients unable to take oral medication, 
particularly where pClrenteral treatment is unavailable. 
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Plasmodium falciparum malaria causes hundreds of 
thousands of deaths annually, especially in children in 
sub-Saharan Africa. One of the most important reasons 
for the high mortality is delay in receiving effective 
medication. Rural health workers and even parents can be 
taught to identify the symptoms and signs of severe, life-
thrcatening malaria.' However, many patients with 
malaria of increasing severity arc not able to take 
medicines orally. Many of those living in malaria-endemic 
areas do not have ready access to health t~lCilities that can 
provide parenteral treatment. For patients unable to take 
ural medication, delay in access to prompt injectable 
therapy can be fatal. Progression from being unable to 
take oral treatment to severe malaria can happen within 
hours" Once the opportunity for early therapeutic 
intervention is lost and organ failure has developed, the 
prognosis worsens substantially and survival depends 
largely on the health-care facility's resources to manage 
malaria complications.' Most patients in malaria-endemic 
areas do not have access to intensive-care facilitics. Rectal 
artcsunatc makes for a rapidly acting and effective drug 
for patients with acute malaria who arc unahle to take oral 
medication where parenteral antimalarial treatment is not 
availahle. 
WHO (UNDP, World Bank, and WHO Special 
Program for Tropical Diseases Research [WHO TDRj) 
selected artesullate for investigation as a candidate for 
emergency rectal administratilln for patients unable to 
take oral medication, to provide therapeutic cover for the 
initial 24 h after presentation. Artesunate was chosen on 
the basis of its rapid antimalarial activity,'" favnurable 
bioavailability,' and reassuring safety' and etlicaey' 
prot1les compared with other available treatments. 
Despite isolated case reports of failed supervised 
treatment,"lO no evidence exists of stable parasite 
resistance developing during lengthy elinical usc with 
artemisinins." A thermostable suppllsitory formulation of 
artesunatc was chosen since unrefrigerated storage and 
easy administration arc essential where facilities arc 
rudimentary. 
In (Jur study, the absorption and initiallhcrapeutic (but 
not curative) etTicaey of single administration of 
suppositories in a dose of 10 mg/kg rectal artesunate were 
recorded during 1997 and 1998 in Malawian children 
presenting to the Quecn Elizabeth Central Hospital, 
Blantyre, and in a smaller number of South African adults 
presenting to l\1osvold District Hospital, KwaZulu Natal, 
all with moderately severe malaria. Because intensity of 
malaria transmission is low in South Africa, these adults 
are unlikely to have acquired any protective immunity. A 
few patients received standard treatmcnt with repeated 
parenteral administration of quinine ffllm the time of 
admission. The study was confined to patients regarded as 
having moderately severe malaria, in the absence of organ 
complications indicative of severe malaria, to establish 
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proof of principle in patknts not at immediate risk of 
dying from the disease. Since artcmisinin derivatives arc 
the most rapidly acting antimalarials known,' the rate of 
early parasite clearance from peripheral blood within the 
first 24 h after initiation of treatment is a sensitive 
indicator of drug absorption. Clinical response to 
treatment, and concentrations of artesuna1.e and its 
met.abolit e dihydroartemisinin in plasma, were additional 
outcome measures. In both study groups, treatment was 
completed with the administration of sulfadoxine-
pyrimethamine according to prevailing national policy, 
and the continued eft1cucy of this definitive treatment was 
also monitored. 
ll1e study aimed to determine whether early 
adm inistratiol1 of rectal artesunate would provide 
bel1eficial initial antimalarial cover, indicated by a rapid 
fall in the density of parasitaemi:l and clinical 
improvement without serious adverse reactioll,. If this 
werc confirmed, rectal artesunate might bc considcrcd 
suitable us initial treatment for patients who cannot be 
treated immediately either orally or parentcrally, to cover 
the period until they are able to reach a health facility for 




In Malawi, children aged (-10 years were cligible f()r 
enrolment if they had consent of their parent or guardian, 
an illness suggestive of malaria, P Jalciparum parasitaemia 
of 20000 500000 ring forms per pL in the blood, and 
features of moderately severe malaria judged by onc or 
more of the following: inability to sit or stand 
unsupported; inability to eat, drink, or breastfeed; a 
Blantyre coma score') of 3 or 4 out of 5; and repeated 
vomiting. Exclusion criteria included any manifestation of 
more severe malaria -namely, acidosis, sevl.:re respiratory 
distrcss, deep coma, shock, jaundice, spontaneous 
bleeding, convulsions, oj' severe anaemia (packed cell 
vl)lumc <lH'%). Children who were enrolled were 
admitted to the national hospital in Blantyrc. Pfalciparum 
transmi;:;sion in this area is ycar-round with increased 
intensity in the nliny season (November to May). 
In South Africa, adults aged 1665 years werc enrolled 
if they gave written informed consent, had clinical features 
of malaria with a P falciparum parasitaemia of <500000 
ring forms per j-LL in the peripheral blood, and were 
classificd as having moderately severc malaria un the basis 
of one or more of the following: inability to cat or drink, 
dehydration, inability to stand or walk unaidcd or 
repeated vomiting, in the absence of WHO critcria of 
severe malaria," or a serum lactate concentration greater 
than 'i mmo]/L 11 Adult patients were admitted to 
Mosvold Hospital, a rural district hospital in northern 
KwaZlllu Natal, where malaria transmission is low 
(annual entomological inoculation rate < 1) and seasonal, 
with peaks between March and May. 
Adults and children with diarrhoea (defined as three or 
more liquid stools in the previous 24 h) or who received 
an antimalarial drug in thc prcvious 24 h, and women who 
were pregnant or hrcastfeeding werc cxcludcd. 
Study design and procedures 
During screening, a detailed history was taken and an 
cxmnination done, with emphasis on assessing severity of 
malaria and nl.:urologieal status. Neurological examination 
included Glasgow or Blantyre coma score rating, or both, 
examination of cranial nerves, and assessment of 
cerebellar and motor function. Parasitological diagnosis 
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was made on thick and thin blood films stained with 
Field's stain and reversed Field's stain, respectively. 
Parasite density was estimated by counting asexual 
parasites against 200 white cells on the thick film or 
500 rcd cells on the thin film, and the white cell or red cell 
count was used to calculate the number of parasites 
per p.L of blood. A sampk was judged to be parasite-
negative if the thick mm reveakd no asexual parasites in 
the fields in which 200 white cells had been counted. 
Blood samples were taken at baseline to measure full 
blood count (Onyx, Coulter Electronics, New York, 
USA), lactate (Aecusport, Boerhinger Mannheim, South 
Africa, or Chiron Diagnostics, Malawi), blood gases (Ilex 
Laboratories J 640 Blood Gases and Electrolytes, Hex, 
South Africa, or ABL330, Radiometer, Copenhagen, for 
Malawi), glucose (Boerhinger Mannhcim Accutest strips 
read in an Aecutest Alpha rd1ectance meter), and 
electrolytes. In adults, liver cnzymes wcre measured 
(Vision, Abbott.s, South Africa) and pregnancy was 
excluded (human chorionic gonadotrophin Combo, 
Abbott" South Africa) in all adult women. 
Artesunate suppositories were administered in a single 
dosc as close as possible to 10 mg/kg, without lubricant, in 
a combination of 50 mg and 200 mg suppositories 
(Plasmotrim Rectocaps, Mepha AB, Basel, Switzerl and). 
Children received a maximum of ti1ree, and adults a 
maximum of five, suppositories. Each patient was closely 
monitored for '5 h to detect expulsion of suppositories. 
Any suppository expelled intact was rcinserted. If a 
disrupted suppositOlY was expelled a new one nfthe same 
dosage was inserted. 
To compare rectal artesunate with standard parenteral 
quinine therapy, scaled envelopes were used to allocate 
one in tlve patients to receive parenteral quinine (Adco-
Quinine dihydrochloride, Adcock Ingram Generics, South 
Africa), using randomisation tables in blocks of size five. 
In all adults and in 17 children this was given as 
intramuscular injection, 20 mgikg loading dose followed 
by 10 mg/kg diluted in normal salinc to a concentration of 
60 mg/mL, with half the dose f,riven in each anterior thigh 
at 0, 4, and 12 h, then every 12 h until the patient was 
able to take oral treatment. In five childrcn who required 
intravenous l1uids, quinine was given in thl.: same dosage 
and schedule infused intravenously over 2 h in hal1'-
strength Darrow's solution with ')'% dextrose. 111e 
llllocation ratio between quinine and artesunate was 
selected to obtain the most data on artesunate suppository 
eHicaey and pharmacokinetics, while retaining a reference 
group receiving standard treatment of known efficacy and 
pharmacokinctics. 's A sealed prerandomised envclope 
which assigned a treatment was opened once the decision 
to enrol the patient had been made. Since the efficacy of a 
single dose of artesunate had not previously been 
established over 24 h in moderately severe malaria, the 
studics were not masked. 
Both artesunate-treated and quinine-treated groups 
were given oral sulfadoxine-pyrimcthaminc (Fansidar, 
Roche Products, South Africa), at a dose of 
pyrimethamine 1·25 mg/kg, as consnlidation therapy 24 h 
after initiation of treatment, or as soon thcrcafter as they 
were able to takc l1uids by mouth. Tberapeutic efficacy of 
sulfadoxine-pyrimcti1amine monotherapy in vivo"- was 
86'/\, (14 day adequate clinical response) in l3lantyre'; in 
]998 and 82'1;' (28 day adequate clinical and 
parasitological response) in KwaZulu Natal in 1997 
(Sharp B, personal communication). Those unable to 
drink at 24 h were given intramuscular quinine until able 
to take sulfadoxine-pyrimcrhaminc by momh. Patients 
were discharged from hospital after parasite clearance 
1'599 











once clinically recovered and were asked to attend follow-
up visits on days 7, 14, and 28 after the start of treatment; 
adults Wl:fe also followed up on day 42, 
The efficacy and adequacy of drug absorption was 
assessed in three ways: rate of reduction of peripheral 
parasitaemia, clinical response, and concentrations of 
artesunate and its active metabolite, dihydroartemisinin, 
in plasma., 
Parasitaemia was measured every 6 h until two 
consecutive smears were negative, and reduction in 
parasite density in the first 24 h served as an indicator of 
drug effect (and, by inference, Df drug absorption), In 
patients with uncomplicated hyperparasitaemic falci-
parum malaria, peripheral parasites exposed to 
artemisinins are reduced to less than 60% of baseline 
within 12 h, and to below 1 o 'X, within 24 h in 95'% of 
cases," On this basis, the primary indicator of adequate 
artesunate activity was set at a fall in peripheral 
parasitaemia to 60'% or less of baseline density at 12 h, 
without subsequent increase above 60% of baseline, 
Reduction of parasitaemia to less than I ()% of baseline at 
24 h was a confirmatory measure of efficacy, Although 
quinine is the current standard treatment recommended 
for more severe malaria, it docs not have a consistent 
dfect Oll peripheral parasite density in the first 1224 h of 
treatment, " 
Patients were monitored closcly fur clinical response in 
a dedicated ward, Vital signs and eoma score were 
recorded at 0, I, and 2 h, then every 2 h until 24 h, every 
4 h \lntil 48 h, every 6 h until 96 h, and then daily until 
discharge, Full blood count, blood gases, and blood 
glucose and lactate concentratillns were monitored every 
6 h for 24 h, Pllracetamol was given to patients with 
temperatures of 38"C Dr greater. Fluids were given orally 
nr, if indicated, by intravenous infusion, Seizures, 
hypoglycaemia, and intercurrent infection were treated 
according to standard protocols, Ability to eat, drink, and 
walk unaided, and detailed neurological assessment were 
recorded daily, 
Blood samples were taken before treatment and twice 
(in children) or fivc times (in adults) during the first 12 h 
after treatment, Concentrations of both artesunate and 
dihydro<lrtemisinin in plasma were measured by a 
validated high performance liquid chromatographic 
mcrhod with electrochemical detector operating in the 
reductive mode by the Centre for Drug Research, 
Ulliversity Sains Malaysia, Malaysia, '" 
The study in children was approved by the National 
Health Sciences Research Committee of the Ministry of 
Health and Population, Malawi, and the adult study by 
the Research and Ethics Committee of the University of 
Cape Town, Both were approved by the WHO 
Secretariat Committee on Research Involving Human 
Subjects, The studies were done in accordance with the 
principles laid down in the World Health Assembly of 
197'5 on Ethics in Human Experimentation and in the 
Helsinki Declaration, Witnessed written consent was 
obtained from literate patients, a guardian, Dr both, 
Verbal consent was normally signed and dated by a 
witness, For 25 children a witness only signed to reaftlrm 
consent during a follow-up visit rather than on the day of 
enrolment; in three children verbal consent was obtained 
without a witness's signature, 
Any patient treated with artesunate who subsequently 
deveit)ped any of the exclusion criteria was also treated 
with p~renteral quinine, 'T'huse in whom parasitacmia did 
not fall below 60'% of the haseline density by 12 h were 
given parl:nleral quinine, unless their condition was 
impruving clinically, 
1600 
All patients were asked to attend follow-up at 7, 14, and 
28 days (and for adults again at 42 days) after cntry into 
the study, A full history and physical examinatinn 
(including detailed neurological examination), full blood 
count, and peripheral malaria smear were taken at cach 
visit, Reappearance of asexual parasitaemia was treated in 
fldults with mefloquine (l5()() mg total dose), whereas 
children were given halofantrine (10 mg/kg every fi h three 
times) on day 7 and either halofantrine or sultadoxine-
pyrimethamine on days 14 28, peR was used to 
differentiate recrudescence from reinfection in adults,") 
Parasite densities were counted by two independent 
microscopists, The study sites were visited regularly by 
experienced clinical study monitors, Data were Slluree--
verified by the investiglltors and clillical stlldy monitors, 
double-checked at the investigation sites, and double 
entered, 
Statistical analysis 
Analyses arc presented separately for the Malawian 
children and for the smaller study of adults in South 
Africa, Analyses were done with Epilnfo version 3,01, 
SPSS version 8,0, and StaHl versions 5.0 and 6,(), 
Categorical data were analysed with Fisher's exact test, 
normally distrihuted data with parametric tests, and non-
normally distributed data with the MannWl1itney U test. 
Parasite and fever clearance times were compared hy 
survival analysis and the log rank tests for the equality of 
survivor functions, censoring patients at the time of 
withdrawal, or loss to follow-up, Both intention-tn-treat 
analysis and analysis of patients who received only rectal 
artesunate or parenteral quinine in the initial 24 h were 
done, All tests were two-tailed with a 5%, level of 
signit1cance, 
Role of the funding source 
\1V1-IO "'DR conceptualised and provided tlnancial 
support for these studies and provided clinical monitors 
for both study sites, WHO TDR had no role in data 
collection or the decision to publish these studies, IR and 
MG, who are employed by WHO TDR, contributed to 




109 children were recruited to the study (figure I), Nine 
were younger than 24 months. The demographic and 
clinical characteristics of the children on presentation 
were similar in the two groups (table 1), The mean 
duration of illness before admissioll was 2,4 days, In the 
month before enrolment, 15 (17%) of 87 children in t11e 
artesunale group and three (l4'%) of 22 in the quinine 
group had received an antimalarial drug (in most cases 
sulfadoxine-pyrimethamine) , 
Suppositories were retained, ilnd no stool passed in the 
hour after insertion, in 70 (HO'Y<,) of 87 children. 
17 patients expelled suppositories, 12 within 15 min of 
insertion, four within an hour, and one at 80 min, most 
commonly with passing a stooL Staff succeeded in 
reinserting the same or new suppositories in all except one 
(l %), in whom attempts to reinsert suppositories were 
abandoned after they had been expelled five times; this 
child was treated with intramuscular quinine, 
Ten children receiving artesunate were l'>>1ven additional 
parenteral quinine according to protocol, six within the 
first 12 h and four between 12 and 24 h, The reasons for 
giving quinine to children allocated tll the artesunate 
group were: repeated expulsion of suppositories (one, see 
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340 children assessed 
87 assigned rectal 
artpsunate and SP 
3 withdrawn 
22 assigned 1M qUinine 
and SP 
2 parasite density 
above limit on recount 
1 repeatedly expelled 
sUPPositories 
[84 eligible for analY~ 
----- ------
--+13 withdrawn 0-:1.2 h I 
I (clinical deterioratio~~J 
IS1 evaluable at 12 h I 
---'~ithdrawn 12-24 h 
2 parasite density >60% 
2 clinical deterioration 
1. consent withdrawn 
176 evaluable at 24 h I 22 completed (note: no withdrawal 
criteria in protocol) 
Figure .1: Trial profile for children In Malawi 
IM=int,amuscular. SP=sulfildoxlnepyrimethamine. One patient with 
parasite {jf'rlsity >60% was given quinine because of clinical deterioration 
celore 12 h. 
previous paraf.,'raph), excessively high baseline parasite 
density on recount (two), parasite density at 12 h 
exceeding 60% of bas dine count in the absence of clinical 
improvement (two), and clinical deterioration (five). Of 
the five children with clinical deterioration, three had 
convulsions (two within the first 2 h :md one at 24 h), one 
developed deepening coma progressing to a Blan1yre 
score nl 2 out of 5 at '5 h, and one progressed to severe 
anaemia at l2 h. One child in the artcsunate-trcated 
group was withdrawn frnm the study by his mother at 
22 h. In accordance with the protocol, patients in the 
artcsunate group received a single dose of artesunate, 
whereas rJ10se in tile quinine group received a minimum 
of three doses Df quinine in the first 24 h (with total doses 
over 72 h ranging between three and seven, median four). 
Curative treatment was completed with oral sulfadoxine-
pyrimethamine in both study groups at 24 11, or as soon 
thereafter as the patient was able to take drugs by mouth. 
i\RT1CLES 
All infections were confirmed microscopically as 
P ./cilciparum and there were no mixed plasmodial 
infectillns. Tne median fractional reduction of 
parnsitaemia at 24 h was 99,9'1{, for artesunate and 41 '% 
for quinine (p<O-OOOI, table 2). Of the R7 children who 
received artesunate, 80 (92%) had a 12 h parasite density 
below 60% of baseline., compared with three (14';1.,) of 22 
in the quinine group (relative risk (l·()9 195'1{, CI 
(H)40'19J, p<()-OOOI). Of the 87 children in the 
artesunate group .. of whom ten had received quinine by 
24 h, 82 were available for evaluation of rarasitaemia at 
24 h (in four eases the 24 h slide was missing or spoilt and 
one child was withdrawn by his mother at 22 h)_ Of the 82 
evaluable patients who had received artesunate .. 79 (96'%) 
had a 24 h parasite count less than 10%, of baseline, 
compared with 3 (14%) out of 22 in the quinine group 
(p<O·OOO1). For both thc 12 hand 24 h analyscs, the 
differences are similar when the artesunate-treated 
patients who were parasitological successes but received 
additional quinine as a result of clinical deterioration are 
removed ti'om the analysis or arc considered as tililures. 
For the four in the artesunate group whose 24 h slides 
were missing, the 18 h parasitaemia was less than 1'1{, of 
baseline in three, and was 19%) of haseline in lhe 
remaining one, whose 10 h parasite density was (j-3%) of 
baseline. 
Clinical progress was similar in the two treatment 
groups. All children made a full recovery. Three of 87 in 
the artesun<lte group and one of 22 in the quinine group 
had a convulsion at some point after start of treatment. 
One artesunate recipient and one quinine recipient 
became severely anaemic and required blood transfusilln. 
Convulsitllls and severe anaemia are features of malarifl. 
24 h after start of treatment, 77 (89%,) of 87 artesunate-· 
treated and 21 (9'5%,) of 22 quinine-treated patients were 
able to drink (p=O-3), and all were able to drink by 48 h. 
The median fever clearance time was 20 h (IQR 14 30) in 
the artesunate group and 44 h (30 58) in the quinine 
group (p<O·OOOI). In the artesunate group the mean 
packed cell volume was 30·5% on admission and 20·0%) 
on the day of discharge from hospital, with :m average 
fractional fall of 14%); the data for the quinine grnup were 
28-9%, and 24·1 %), with :m average faJ! of 16%, (p",O-32). 
Children were reviewed 7, 14, and 28 days after 
admission. 1 '5, 20 .. and 28 patients in the artesunate group 
and three, five, and ten patients in the quinine group did 
not attend follow-up on days 7, 14, and 28, respectively. 
Time to reappearance of parasites was earlier in patients 
treated witb a single dose of rectal artesunate than in those 
administered three to seven doses of parenteral quinine 
(log rank p=0·(35). Reappearance of parasiraemia among 
those followed up on day 7 was significantly more 
common in patients treated with artesunate than in those 
with quinine (14 of71 TJS 0 of 19, p=(Hl35), but not for 
those followed up on days 14 (p·=()-5) and 28 (p:=()-7). Of 
Children Adul15 
-----------------------------------Rect.al artesunate (n~87) Quinine 1M/IV (n=22) Rectal ilrtesunate (n=27) Quinine 1M (n=8) 
Male 54 
Female 33 
Median (range) age 48·2 months (16 120) 
Mean (SD) weight (kg) 14·2 (3·7) 
Mean (SD) respiratory rate (breaUIs/minute) 45 (14 ·3) 
Mean (SD) temperCltule ("C)' 38·7 (1·0) 
Mectii'!n (range) paraslt..ccmrnia (ring forms per ILL) 11lS 977 (10 995--848 732) 
Mean (SD) plasma lactate (mmoIjL) 2· 77 (2"1) 
Mean cell volume 30A 





45·7 months (18 121) 29·0 yenrs (16 58) 
13-4 (3·6) 62 (104) 
46 (130) 24 (52) 
39·1 (1·1) 387 (Ll) 
230738 (4 293--701 784) 54 800 (520-24fi (00) 
302 (0 g) 2·5 (0,7) 
21l·9 39·1 
Table 1: Selected baseline clinical and laboratory parameters by allotted treatment group 
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Rectal artesunate (n=87) ----
Parasltaemla (ring forms per ILL blood) 
Baseline 185977 (112 41.1- 336 ODD) 
12 h 50 S96 (18 771107 698) 
% basc,lille 267% (13,842,7%) 
24 h 222 (37,-625) 
% baseline 
PCT (h) 







1M/IV quinine (n=22) 
230738 (170 078-325 (29) 
210335 (170 078325 029) 
82,0% (62,5102%) 





p Rectal artesunate (n=27) 1M quinine (n=8) 
0,69 56480 (26536-1.26000) !:i8 340 (45 110-118230) 
<0,0001 5560 (1 295,25 840) 35160 (22 720 80 4(0) 
-cO,OOQ1 12,8% (3,233,8%) f34,7% (35,5 B55%) 
<0·0001 400 (120--1 0(0) 17320 (4 98037 403) 
<.0·0001 1% (0-3%) 275% (5 58·5%) 
.---. ----------------









Duta are median (IQR) unless specified olhcrwise. IM:..:...intramusculm. IV-intravenous, PCT,:,:",parasitc clearance time. t test. 
Table 2: Parasite density over time by allotted treatment group 
thllse patients who completed 28 days of follow-up, 34 
(67';;',) of 58 treated with rectal artesunate and five (42%) 
of 12 treated with parenteral quinine had had a positive 
parasite smear by d~y 28 (relative risk 1·61 195% CI 
0-813'2" J, p=0·11). Recrudescence was not 
differentiated from reinfection in these children. The 
44 patients with recurring parasitaemia were either 
asymptomatic or had features of uncomplicated malaria-
namely, history of fever (29), vomiting (six), decreased 
appetite (seven), cough (four), and abdominal pain (one). 
None was associated with severe or moderately severe 
illness. All patients had a normal Blantyre coma score (5) 
and tolerated treatment with an oral antimalarial. No 
deaths occurred in this group. 
South African adults 
Of 5) patients screened, 36 met the criteria for the study. 
Of these, 28 were assigned to reeeive rectal artesunate and 
eight to receive parenteral quinine (figure 2). One patient 
was not given the assigned artesunate because he admitted 
to recent use of an antimalarial on requestioning. The two 
groups were similar in most clinical and laboratory 
variahles (tahle 1), in duration of symptoms (median 
) days range 1-6), and in previous treatment of the 
currcnt iIIness_ Sevcn patients (20%) had taken 
antimalarial medication more than 24 h before 
53 adults assessed 
/------11>1 17 excluded 
36 adults randomised 
presentation, whereas eight (23%) reported use of 80-
called traditional home remedies, of which rectal 
administration of commercial shoe polish (in six of eight) 
was most common. The other traditional treatments were 
rel.:1al toothpaste and liquid soap enema. Two adults 
expelled artesunate suppositories (at 5 min and 100 min).; 
the suppository was successfully reinserted Of replaced in 
both. 
One patient in the artesunate group received oral 
sulfadoxine-pyrimethamine, in error, at 0 h instead of 
24 h. Two in the artesunate group were given additional 
parenteral quinine according to protocol: one patient had 
a parasite density exceeding 60% of baseline at 12 h, and 
the other developed mild clinical jaundice at 24 h. Four in 
the quinine group had a parasite density exceeding 60% of 
baseline at j 2 h. Metloquine was given to one in the 
artesunate group on day 7 for persistent parasitaemia. 
In adults the results were similar to those in ehildrcn 
(table 2) ie, signiticantly faster parasite clearance in 
those who received a single dose of rectal artesunate than 
in those given at least three doses of parenteral quinine. At 
12 fl, parasitaemia was less than 6(]'Y., of baseline in 26 
(96%) of 27 patients allocated to artesunate and in three 
(38%) of eight patients allocated to quinine (relative risk 
(H16 [95% CI 0'01-0'44], p=()·0009). At 24 h, 
parasitaemia was less than [0% of baseline in 22 (81 %) of 
8 assigned 1M quinine 
and SP 
27 of patients allocated to artesunate, 
compared with three (38%) of eight in 
the quinine-treated group (relative 
risk 2·17 LO'875'41], p=(Hl27). The 
median fractional reduction of 
parasitaemia at 24 11 was 99% and 
72% in patients treated with 
artesunate and quinine, rcspectively 
(p=0·007). Of the 27 artesunate, 
treated patients, TWo had received 
quinine by 24 h (one at 12 h and the 
j not treated with s ludy 
drug (prior antimalarial 
use on requestioning) 
27 treatnd with sludy drug 
2 witt1drawn before 24 h 
1 SP given at 0 h 
1. >60% pclrilsilaernia 
at 12 h 
eVClluable at 24 
Figure 2: Trial profile for adults In South Africa 
IM'"intrnmllscular. SP~suljadoxine pyrimethamine. 
1602 
;1 Withdrawn before 24 11 
(c>60% parasitaernia 
at 12 11) 
other at 24 h). Results are similar 
when the artesunate-treated patients 
who received additional quinine are 
removed from the analysis or are 
regarded as having treatment failure. 
Clinical improvement was similar in 
the two treatment groups. All patients 
with moderately severe malaria 
tolerated oral administration of 
sulfadoxine-pyrimcthamine at 24 h, 
and subsequently made a full clinical 
recovery. None developed severe 
malaria according to WHO criteria. 
One patient (artesunatc group) was 
regarded as having progressed to 
severe malaria on the basis of mild 
clinical jaundice at 24 h (although 
---------_._._---"----
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bilimhin was not measured) and was treated with 
parenteral quinine. The jaundice had resolved by the 
t(lllowing day. There were no deaths. Median fever 
clearance time was more rapid in the quinine group (23 h) 
than in the artesunate group (36 h), although this 
difference was not significant (p=0·116). 
32 (9] 'X,) completed 42 days of follow-up. Three (two 
of 27 in the artesunate group and one of eight in the 
quinine b'Tllllp) were lost to follow-up, but were reported 
hy family members to he well. One in the artesunate 
group was parasitaemic but asymptomatic on days 7, 14, 
and 42 (a recmdescent infection shown by PCR) despite 
treatment with therapeutic doses of both sulfadoxine-
pyrimethamine and metloquine. No other patients were 
parasitaemic as shown by microscopy between days 7 and 
42. Five had P Jalciparum-positive PCR results,1I 
suggesting low density asexual parasitaemia or 
gamerocytaemia. PCR suggested recrudescence in four 
(1WO of 25 in artesunate group., two of seven in quinine 
group, relative risk 0'28 [95%, CI 0'051'65], p::-:()'211) 
and reinfection in one (in artesunate group). 
Tolerability 
A single dose of artesunatc suppositories at a dose of 
J () mg/kg was well tolerated in both children and adults. 
"nlere was no significant difference in frequency of 
adverse events (defined as any new symptom, or 
worsening of any existing symptom, sign, or abnormal 
laboratllry value) between treatment groups. Other than 
local reactions at the site of intramuscular quinine 
injection in tJlree adult patients, the few adverse events 
that happened could have been attributable to fa1ciparum 
malaria or to pre-existing disease. Careful clinical 
assessment of the central nervous system detected no 
signs of adverse neurological events after administration of 
artesunate, although one patient of eight in the adult 
quinine group developcd transient dysdiadochokinesis. 
Pharmacokinetics 
Artcsunate, its active metabolite dihydroartemisinin, or 
both, werc detected in the plasma of all 27 adults and in 
H4 of H7 children. The minimum detectable concentration 
for artesunate and dihydroartemisinin was 4'() f-LglL. 
Concentrations of any drug in plasma did not correlate 
with parasitological or clinical outcomc, and striking 
intcrindividllal vari:nion was noted (data not shown). 
Discussion 
We have shown that rectal artesunate, given in a single 
dose of 10 mg/kg, has rapid antimalarial efficacy within 
2'1 h of administration in moderately severe faleiparum 
malaria in children and adults. All patients had either 
pharmacodynamic or pharmacokinetic evidence of 
<lhsorption of the drug. Clearance of asexual parasites 
from the peripheral blood was consistently faster with 
rectal artesuntlte than parenteral quinine, as is expected 
when an artemisinin is absorhed adequately. The results 
were highly significant not only in the large study of 
children, but also in the smaller study in adults, which was 
powered to detect only large effects. The clinical and 
parasitological responses show that rectal artesunate 
provides effective initial management of acute malaria in 
patients who cannot take medication by mouth, 
particularly when parenteral treatment is not available. 
A faster decrease in peripheral parasitaemia does not 
necessarily ensure improved clinical outcome. In this 
study, [he clinical success rate for rectal artesunate was 
similar to that for parenteral quinine. This is consistent 
with other studies comparing intramuscular artemether 
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with intravenous quinine in severe malaria, where 
artemether showed more rapid decrease in parasitaemia 
but equivalent clinical outcomes,22 
Fever clearance time'> are shoner in artemisinin-treated 
patients than in quinine-treated patients." Rapid fever 
clearance is an important clinical benefit, but it docs not 
reflect cure and might create a false sense of security since 
combination with a second effective antimalarial agent, or 
a prolonged treatment regimen for 5-7 days, is required to 
achieve cure.17 Health-care providers need to ensure that 
patients or caregivers understand the need for further 
curative treatment at a referral centre. 
For the purposes of this study, the dctection of 
artesunate or dihydroartemisinin in the plasma WllS taken 
as a secomhiry indicator of drug absorption, as the 
therapeutic drug level of either is not yet clearly defined. 
Despite the consistent pharmacodynamic effect of rectal 
artesunate, retlected in parasite clearance, we found 
marked interindividual variability in pharmacokinetics. 
""Ibis is consistent with the variability described for the 
artemisinins.' lnere was no correlation between 
pharmacokinetic measurements and parasite clearance 
rates. The relevance of pharmacokinetic data from 
unbound plasma concentratio s of artcsllnate and 
dihydroartemisinin needs tll bc confirmed hecause these 
drugs accumulate selectively in infected erythrocytes." 
A single administration of rectal artesunate alone is not 
intended to cure malaria. Although repeated 
administration of parenteral quinine and artemisinin 
derivatives arc proven effective treatments for severe 
P JalCljJamm malaria once a patient is admitted to 
hospital,"" short-course trcatment with either is 
associated with recrudescence unless followed by full 
conrse of effective consolidation treatment. 29 •W Rates of 
recrudescence indicate both drug exposure to the initial 
treatment (to which no resistance is proven in Africa) and 
the efficacy of the follow-up treatment, which is highly 
dependent on the prevalent patterns of drug resistance. 
Widespread resistance now precludes the use of 
sulfadoxine-pyrimethamine for completion of treatment in 
much of east and southern Africa." 
In our study of children in Malawi, the reappearance of 
parasites occurred significll1tly earlier with artesunate 
than with quinine. Reappearance of parasites at 7 days 
suggests that a single dose of artesunate followed up with 
a single treatment with sulfadoxine·-pyrimethamine at 
24 h did not eradicate the infcction. Thcse findings 
emphasise that treatment with a single dose of rcet,\] 
artesunate should be completed as soon as possible with 
an effective antimalarial. Sulfadoxine-pyrimethamine was 
first-line treatment for uncomplicated malaria in both 
study sites. Despite reported therapeutic efficacy of 
sulfadoxine-pyrimethamine monotherapy in uncompli-
cated malaria bcfore our studies, parasitological failure 
rates had increased to 7f1'7"/o by 1999 in the Malawi site 
and to 88%, by 2000 in KwaZulu Natal."·" 'I11e earlier 
reappearance of parasites in artesunate·-treated patients 
might reflect the facl that they received a single dose of 
medication (at the time of admission), whereas patients 
on quinine received a total of three to seven doses (over 
24-72 h). Late parasitaemia could be due either to failed 
treatment or to reinfection. Our study in children was not 
dcsigned to distinguish between recmdescence and 
reinfection, but rather to establish tile benet!t of ~ single 
dose of rectal artesunate over the initial 24 h. The 
addition of 3 days of artesunate to standard antimalarial 
treatments has been shown in most studies, hut not all, to 
substantially reduce treatment failure, recrudescence, and 
gametocyte carriage." 
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Careful clinical neurological examination in our studies 
detected no signs of neurotoxicity, which is consistent 
with other human studies of the 
although few data are available in young 
neurological examinations arc less reliable in 
under 'i years of age. '3,JO Concerns about potentj[JJ 
neurotoxicity stem from an unusual pattern of 
the brainstem nuclei induced by 
artcmcther and anemotil reported in animal studies.n .w 
The single dose of the water-soluble artesunate in our 
study j" less likely to hlwe toxic effects than a full 
treatment course. 
Our study was confined to patients with 
severe malaria, presenting to 
close observathms could be mflde. l\1any 
potentially Iife-threfltening malaria have 
dise,lse than those in this study, with 
coma, severe acidosis, severe anaemia, and 
pulmonary and renal function. 
studies confirm the 
administration of 
or 
in severe malaria in adults,""-" further 
needed to confirm this benefit in 
benefit of initial management with a 
dose of rectal artesunate in with severe malaria. 
Studies arc done tn the 
administration of tectal artesunatc in the context 
of remote rural communities in Africa and Asia. 
Although artcmisinin derivatives have been 
in southeast Asia, this is not yet the case in Africa where 
they have a potentially important role, both in combination 
therapies and as pmmpt treatment of life 
threatening malaria. Our results 
children and adults with malaria of 
arresunatc given by suppository is effective in most 
individuals and is well tolerated. Artesunate cn""'''~IIT'''rlf'< 
can be given safely by personnel with little even in 
the home. Sratl~ patients, and parents should be informed 
of the need to watch for the and 
of the need to ensure follow~up with an t"tt(>cT,V{' 
treatment. Patients and their relatives 
use of rectal treatment in this 
administratIlln of rectal artesunate does not deter 
from reaching a health-care facility that can 
effective antimalarial treatment and ;,nnr'"ln,r",'r(> SlI1P1POlt1l\'e 
management, prercferral rectal artesunatc has the 
to reduce malaria related morbidity and 
treatmem is of greatest relevance 10 communities in rural 
areas of malaria-endemic which bear 
the heaviest malaria burden and for whom 
treatment is often not avuilable. 
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The Role of Artemisinin-based 
C,olnbination Therapy in Malaria Managernent 
KAREN BARNES. PETER FOLB 
UNIVERSlTY OJi CAPE TOWN, SOUTII AFRICA 
INTRODUCTION 
Background 
M,tiarj.! I!lm !lidity and ]ll(Jl'tality in Africa is rising, and lliis 
h principally" rcslIJt or inC!'c'lsing cliloJ'O'Iuim' anel sulfa-
d()xilll"'[>yrilfl('lil,lIlli1l!: (SP) \'(.sisl'l!ICC .Hld (Iday,s ill aecc.ss 
10 df.'Cliv(' rll<:lilpyl! Alililnal,jJ'j,-d l('sislannl leslllts in all 
jll('l("\"" in In-l,lIJrlcn\ fail"rc', pI'IlIUlIW'cl ilin1'ss, l><,spilalisa-
t i()lI "ltd death "s well as iIlCl'l'asC'd 1lI,,1;lria Irall"ni"ioll, 
pall iC'llbrly oj' 11oshl;)1l1 palasites, Drug Icsislancc h W'fll'l'ally 
ulldewSl illialed and f'"licy challge is COnlPic:x, slow and 
(m!ly, H'sitiring in significanl ddays in clLsuring all dIeeli\'(' 
lIl'lioui,1 11<'.11111<:111 policy in Ill<JIlY mabria--c'n<iemic counlries, 
III ;"tdilion to n'sistalIC(l to tll('Llpies, th" othtT irlljlortant reil-
se,,! 1'01 tll" 1 tip,ll llHlrLllily frulIl lIlalarb h dcl"y ill l01cdvilJg 
"n,'clive JlIedicaUoII_ Rural health w()rker~ "nel lIVllll par"nt!. 
call b" lallgllt to identify Ihe symploms and signs of 1iI,'-
thnld!<'llillg I mdaria." I-jow"vel, lIlany palienls wit], mOl'" 
Sl'VI'f(' Ilialmi" are n()t ahk, 10 take medicines orally iJC1CH"" 
Illlly are confused, rtnctlllsciUlIS or vomiting, COlw(mUoliai 
Illerapy for "'ven' Iflalaria, ill "tldirJUll (0 (lit' highest lew,,1 of 
\\'I'portivc: CIl]'(, available, is i1lj('clalJll' (paretlkral) ']lIil Iii Ie, 
1\ eomideralJi<> pmpurtioll of peopl<, livillg in IlWlaria-Ilnch'lII-
ie "IC," do !lot IIllVC ready IK'CC'SS ttl iH-,aitiI facilili,'s ahl" 10 
[llOVi< I .. I,arc!!t"r"l Ireallll('nt. For P,lt ;"llIS unable 10 take onll 
nw<ii, dll(lIl, delay ill au!,'," to pmmpt p,lrenteral iJlUJ'aIlY call 
1)(' I;lt,,]' Progr('"iOll I'm II I heillg IInable 10 take ond I reallll<'1 It 
to ,('vnC lI\,ilariil call occur within hOllr"l Once, the op[lortll-
!lily for cady IhuroIj>Clutic inl!'IVl'lltiun is Iml and organ f'ailUl(, 
lias d('wloP"d, th" I'rogllll,j, w[)rS"flS considPl'Clhly and slIrvival 
,it'f)(llllb a g 1'('<1 I deal on dec"" t() a heillthcarc r .. cility with 
1\'.~,()\lln>\ 10 1I1tlllagc rnalaria CUIIlplicaUun\.!) S\H 11 LH_:i!itie~ are 
,\CilJ( (' ill Inil!;lria-cnd{~nlic counLl'ie~. 
Rationale few lise of arternisinin-based 
con1bination lherapy 
i\rlLllnhiniIl b 111c active antimalarial compollClill isoldted 
1I'<JlTl Iht, Illeciicinal heriJ Artemisia .1nnua, which has been 
lIS('d for u'nilirie, in China a" a IraciilirJII,tI tn,atfllfCni. for 
ft:VCT <-IJld !11<llaria. In n~cel11 year;..., ar1(~1l1isil!iJ: (It;rivilth,e~ 
Il.W" beCOlllll tl1<1 focus 0 f world wide ilileniiofl iJ I the Iighl 
of emm'ging resh!ance of Plasmodium falcipaJ'lllll to first-
lill" drugs; to dale n1sistancc to arlcntbinin has n(ll been 
d('IllUlls(rateli ill malaria paraoites, While arlemisinin dl'riv-
alives l'l',-]uire at 1u"sl seven days of lrt'atmenl when admill-
istered al(jm~, wilcn comlliliccI with otlwr l'irsl,-lill<) cinlgs, 
call LT,\d-
iC;Jte I'dldSil(', (jllickly aIlcl pmll'cl dg;lill\t 111<) cicvc:lo[lllIt'llt 
of resistance 10 both dnlgs, 11l1[H'ov('d ('\In, ral"s "lid 
cie(T(:<lscci gamducyle carri;lge Il,Wle iJel'1l cUllnrmed ill 
lililiteci African !'kld tdah."-' Artelllisinin <illl'ivalivl's are the 
only f'irst--linc llIalari" Ireatment'; to <lei on gillllf't()cytes 
(11\(1 stage or the rnalarllJ para"He's lif'e cycle rcsp()Jlsihk I'cn 
ongoillg Illalaria transmissiLln) thcrllby potetlt i,dly reducing 
malaria transmissioll ,mel partiClllarly II", Iran<,mission of 
resistant straillS of lllalaria, TII(> principle of usillg cUllliJina-
limJ ther<lpy 10 cil'lay (he ('Jlll'rgl'llcc alld SI"bld of n)sisl--
aile,' is cslablisi-I<-)d itl IlIe HiiUIOlgllflH111t of tlliJ('J('lilosh illici 
HIV, <lJld is expeclultu apply cCjllally to malaria," 
This d];lpter will explore the role of artelllhillin-lJ<h"d 
COlilbillaliulis in addre"ilig till' illLTeasillg Jnorbidity alld 
tllurtalily ill malaria-ell<l"lllic countri"" cithllr wllell 
ilcilllinistenld ()mlly for 1l1ll'olllplicalNI lllalari" or as a 
supposilory ill "lor", SCVlli'<-' lIlaiarin, 
ROLE OJ' EVlDENCE 
Sdllctioll of [\Ia!aria In';llnH'lIt O('(,llrs oil Iwo levels, Ihat or 
policy makers and lilat of individual Ile;~lth cart1 pl'ovidl'ls 
(both f()rmal and informal), Poli<-y makers rcqllil(' 
(-'vidf'rlCll !o delllrminc, whe1l mnLlri;; treatmenl policy 
should be cllanged anel 10 ,dect which antinlillarial(s) 
,lIolild replace the ClllTcnl trealllll1nt, HC"<llllI cal<' l'J'Clviders 
are illfillerweri by avallilbility of ;tHUmalaria! tn'atments 
(which in the public sectnr b ofL,'n gUided by malaria 
tJ'c'aIIlH'1l1 policy and tilt' ess(!tltLII dl'llgs progrilHlllw) 











Box 1. ARHMISININ DFRIVATIVlS CURRENlLY 
WIDt.LY AVAILABLE 
III AIZTEMETH 1:1:': 
.. i\RrElvllSINJN 
.. Ai<TFSUN/\,TE 
.. CO-A l<TEMETHER (,,1'1""1C111<>1" phis lurndal 
.. D1HYDI<UAI:':TEMISINfN 
Art.('misinin-based Combination Therapy 
Willi th" possible "xcepiioll of artemisillin derivativ(:s, 
l'l''oiSlallCC of P fakipanllll to all available 
Tlw dficacy and safely of arl.'Sllfl;lI" in cOIIlbination will! 
sulradllxine-pyrirneti1arnill[' (S1-') has been teValll"lcd ill 
r'mclombed C011t1'OIl,,(1 l,-jab involving 28G5 (lalit'lIl, in 
sllb-Sallaran Africa (1;lylor "IV, p''l'son;tl COllllrtlllli( ,II iOll, 
2(03) l<eslllls frorn Ihe firsl study pulllbhccl [lUll I The 
Call1lli,),'' wl1me the cure rate witlt SP rnollollierallY b ~13'X" 
silowcd I hal both cun, rllt<c and parasite cJ(,'arallCl; wen' 
significantly higher in p~tienLs who rc('('il'l'ri 3 day, of arll'-
sun a!" plus a single dos!' of SP cOlrlpared wilh ('host, who 
rc:ccivecl SP "lone. Call1et()(yl(~ carri.lg<' was G8'Yr, following 
SP trealmenl in (,OJnparbon to 21 % following comhinnlion 
tre"lnit'lit (p c- [l.U(1) 
The larg",1 series or lI1<'r"p'''llic ,·:I'fiucy sludi", willI ,,,1(:-
sllllal,' pIllS mdluquine dell1011strille a slisiailll:d incre"",d 
Clile rail' (alll1osl 1 o [)'X, fnJIlI 1 0~18 ollwarlb), clt:spil,' liw 
LOsl"blbl,,'cl resislmlct: [1l1l1enl S""II for Iligh·do,,, rndlu-
quill" "IOllf', bel ween 1990-04, 1'1 ior I () lj,;ploymelll of 
drles!l"nlc: plus mdlo([llim: (Figltn, 1).:1 
allcl'll<lliv,'s I"" lWeI] ii''''1l1cnliy <locumenlpd.'l 
J\ncllli'oillill d'crivaliw,s w,ed aJone arn il'oS(Jciated 
wit I, high I n'aifl\"IlI fail< Jr(-, ra1es unless admini.\-· 
Ic:red for S"Veli d'lyS, whic11 is nol un"" acl1ievcd 
as symploms "n' generally rdievcd within Iwo -
Ihree days. Thus, ar1"'lllisiliin derivatives slioulel 
ouly be IISl,d ill C()rniJilialioli wiLli It second cllcc-
live anlinuilarial; pOOl <'fTicacy of Ihis cOlllpollenl 
signiticiIIllly cOlnl",,"d,l's Ille d'ficacy of Iii" 
('ollliliIICllj,'IL [,zesulls prl',selll<:d below fOCII\ (JII 
(,llll'I'llllv ;,vllilaiJJe (,OIniJillilliollS Ihal an, cHI,,;r 
[lllcl(lI!'.,·t! logell",r 01 m'lIluf"Ullr"d ,,~ a fixed 
<ill,'(' cOlllhilliiliOri. Thew arc " r,ulnb(,r or 
lIrlmnisillin-h,m;d corniJinali(lIlS cllrr"lIlly lm<ler 
.h;ve\o[lllJenl, wilh dil'lydru-arl"lllbillirl pillS 
pipUI;)ljltiliC ,uIlI ;ul"SIlildle plus dllorploguanil--
dllPSlllll' Illosl likdy I" I", widc:ly ;,vailaiJk ill 11ll' 
HH_'diIlJlJ I ('Ill\. 
F1CURl'l. ClJMUU'\I'IVE CURE RATES (D5(){, Cl), ASSESSED 
AT DAY 28 FOR DIFFERENT REG [MENS FROM PROSPECTIVE 
i\ '"lIsid"l'ilhl" clinical cvidel ICe [Jim, has bC'l'1l 
",I;II)lisi1cd l!trough llie largesl randornised COII-
IloJ["d Irials ever condllclc'd on anlimalarbls, 
d,'IIIl"i\lrating lilat arlmllh\i';lI-h~sed c()rllbina-' 
~ r)lf·l1()fjlJilw (I" IJ1g/III'J 
I11fd]<l'1u;ne (2:jmg/kl~ 
(\ftr:S\Hut(~ (4 mg/kg for 1 day$) with mt.:;t1oquine (2~; lllg/kg "pllf dos(~) 
j iOlls Illlpruvc CUll: nlle<..;, (leCrl'iI\C gal Iletocytc cl1rri<lg(~ ;It 1<.1 
an' w<'il lolerated witll few ;('riml::' aliven,e dfeus (Taylor "Iv, 
pe;r"",," UlIlllllllllicilliOrl, 2[)03).ln Ihe first of Ihe·se Illlllli-
('('nln' Iriilh 10 I", published, !)41 c1tiklrlc'1l who had UllCotll-
I'lic<ll"d P 1';II('il';1I 11111 lIlahrh wc:n: randolldy assigned three 
days I mallll"lil witlt ,ullucUaquine pillS artt~;,llllale or arnodi-
a'illil'" pili;' placC'iJo. Bolli n:gilflens were well lolelnlcd.TIl(; 
c()ml,ill~li(JIl of mlC,Sllllatl' and al!loclia'1uille sigllif'icanlly 
ill'l"[;v"d IWillnll,nl efficacy ill Gabon 8G% vs 71%, 
(p and KellY" fi8');" vs. 41 fYt, (p<C)OOOl), ;iltllollgh 
('\ Il C' 
1';11('\ for ar!lO<1i;-HjlltllC'··artl'\\lU;\lC' Vl'l'.\U.'::! 'l1llodlaqlljll(, \V{~\C 
8?% vs. 7()'K, (]I OJ) ,II> 
Aricmellll:r-lurnefanirine is trw fir,sl fixt·c\-dose cOllliJinal ion 
oj' two anlimalarials that WilS nol Widely us(;d prior 10 being 
rnarkcl"d, A Coclirallc .sysl<:lIlCllic I'l-'vic:w uj' r,mciOlllis"tI and 
qllllsi-randolllisI:' I Iriah cO!Ill'arillg arlelnetll('r--IUllldant rine 
adminislf'H:d orally with siandard trealml:lll rq.;illl"llS 
['i1loroqu im" SI If f;l(loxillc-pyrill",IIIlIll] inc or nwn"'1,lilIP) 
I," 111(1 only I wo trials wi len; pari icipillilS rcu,iVf,d 11 Ie 
n'cOllllllentied filII six duses of i1rtplllellit'r-Iullldanll irllC. 
The,st' sitowed no difference ill Cllre lill'" from nrle,SUllllk 
plus IIldlo'lllilll',l:I Six Irials wilh 1 [;98 participanls tesled " 
['our-dose r<'gillll'''. Failurt, rill('\ fur" ['(JIII'-doM' r<'gilTll' "f 
arluJll:I1tI:r-illllld;llllrillf: wert' Jligiler I it all slalllJ;\l<! 










Iwlll'l Ihall cllioroquine ill tW() studies, Ille j'nilure rale for 
dJimuquilll.' "I Il", trial ,Hes wns ow'r 50%, 
Ar'lesunate 
Arl('.',lIlJak ('all be dcilllinblewci '1S a t .. hl"I,.t1l illj(,ction, or ilS 
a .ed,,1 ,'llppository A nlillparboll of illlr<!"te"ow, ",r!esLlllal" 
and (["i!lim.' ill 113 <!Clul1$ with Severe malat i" 1'C1'orleel wor-
tillily "I' 17,% with arkSUlinle illld 22% willI ql1illinu 
(I' O,(2)H hi palil'lIl\ willI hyperparasiliH.'lIliC! v\'11O had lIO 
oil".'r 1','allill'S "I "'VI'I'<' Illalaria \)llt were al an hlcmil""l risk 
of (kv<:ioping ,,,,v(.'r(; 'l1aiilria, oral arie,sunate was found to 1>1' 
Sllp'Til)(' 10 illlrav!)!IlH" quinine ill rc<iW,'illg IlOllt clinical 
sYIllf>1 (llllS and P'" asil I '.s, I', l~ cctally"nlilllinisi erc:d ill'1 !)S1 II lOll!' 
h;" h"(;l1 s!town 10 he "ire and llighly effeclive ill I'hildn:n 
alld adlliis willi UII('olllplicated or modur'lldy ",w,]'(: falci-
pal'llll! 11leiada.",17 A ntlllll",1' of I'"cent randOlllis"d con-
lrolled and Ol'''ll label )\wlies of r"clal art""lrIate ill Africa 
alld Asia Ilavc dmllonstrall'd 1 he rapid Ilntilnalarial efficacy of 
it single dosc of Hectal ilrteSUlI<lle (1 D Illg/kg) in mod!cralely 
sevem ra1cil'arulll malaria ill bolll childn'l'1 a11(1 adults prior 
10 1,,1"'1'1,,1 for ddillitivc trc;ltllll'lll. All pal ients ha(i ()Vidence 
"f ad'''lllalc alJwl'1'1iOlI or Ill" dnlg, Clearance or malaria 
I ).\1 "sites 1'n!l11 Ihe periph<:ntl blnoel was consisknlly mo!'l' 
rapid willI J'(,('t;1I artcsurJaI.!, tll;111 with (j\lillilll' injectioll 
TIlt'S<' dillil'al dlld pimlsi!oiogical n'SIHlI1ses Sllggc:M Ih;;1 me-
1.11 illl<'sullille could I'rovld" meful inil lal manage'IlIPIII of 
.Inlli' 1 1\; ti; II i;1 in path~llh \vilu canno1 1ake 111edicalion Ii)" 
11((".111 a till ror WI\(lI11 parcnleral tre~llllenl may llol ill' 
avaiL11,1(', Tlll'lt: ;lrl' Zibo a Il1IlllilcJ' of ~Ir!all "[WI! hlbel ,Iud-
h:~, ~Olll" 01' \Vhich \Vere ramillltliscd, demollslraling 11,(, 
c1illical allli parilsllulogical elTicacy of n'cl:lI 1I11","l1al(' III 
zlti"ll!> wilh 'CVl.'rc P f'licipanlill ini,,:clions'" wlii'I'" 11-<'1,,1 
aJ'leSlllml" wa~ "dmini,sll!J'cd n:pcdtcdly and was COl1\iJilll.'d 
SI''111l'llt ially wll h il SI'colld "r,iI ill II ll1\alar lal to prevellt 
l'eCnH!u~Ce[tce (n-~l-q)l)t:aran('t-~) of lllalari:-L 
Snf(~ty or ar·t~misinin derivatives 
Arll'rtllsillin ;Hld its rim'Ivallves hav!' bel'll used cxl"nsively, ("PI" 
dally III SuutheRs! AsI<1, for the !malHlenl or P fnicipan.ll11 lllahn·, 
la will! very liltl" cvi<iel1n: or loxi( ily l\111~t of tile COlleenlS 
rq~,"dillg lile safety oj' arll.'tllisinill dtTivalives an, based on anl-
1I1,li silldi"s or on nlild 10 modcratIC adverse ('vents tilal liave 
IWPl1 reported liom ciillical Sll1ciit',\ I'll" However, urdy a fl"w 
st\ldie~ hive illcimkd young childwil in Africaii COliCCIT" 
,<1)0\11 P()lCIIILli Ill'lIrotuxicily ~km frolll 'llIitll,,1 ,\1 udies tl1al 
SI'OWL,d 'ill 1I1l1IS11,,1 pallerll or daillagl.' to till' l)r,lilLstl'rll 
illdllceci by lligh do,\(' (> 15mg/kg/ dq for l'1 days) 
pal"'lll('l'al 
[lj'(JI01IgI'11 
ill Il~1 nnlll(:i 
C(ll tia tilTlC 
aw! art,,{;lh('1'. A1I1I()llgll 
was oiJservl'ci in Iwo 01 lill!'(, 
r'"I<iolllhl'li conrroll"d Irials cOinparillg arlenwlher wilh 
qllillill(, in Ihe In'alm!:!!1 of cerebral !!wlaria, a mE'l<l"illlalysis 
found 110 increased risk of prolonged COlli" in tilP 
!lriL'lllbinin derivative-treated patients," Alliopsy or falal 
~ev(::'r(' n 1,~l{-\ria ca\cs p.xp()sc(l to <u'1 enlis]! Jill tjt:rivat iv{-~\ t{ llln( 1 
no ('videll!'e or neurol()xicHy. Tilere Ililv" !Jcen sp(JI'adil' CllS(, 
reporls of impaimd balance), nyslagltll'" fill(' Illolur c(I()nlina-
(iOll, paraes1hc:sl;-1 (lnd .')eiZlll'e~ foI!OV . :i!lg II'('aIIIH'11I of ,\ev(:re 
faicipanllll lllillnl'ia witl! an Clrturnisinin derivative, However, 
cOlicomilant adlllinhlratioll of rndloCjuinc and malaria itself 
may l,ave cansed tll!;s(' TIC'umlogical abnormalities, 
Clinical stlleli!.'s lla\,l~ reporled prurilus and llliid skin rasl! iII 
I-I/ r){, or palle'lIls receiving arlL'lnisillill-iJascd combinatioll 
IIlPrapy, willl a high(:!' incidence ubserved with Ihe; c(J[Jcur-
r<~1 \1 adloinhtrall011 of ,I)ulfadoxine-pyl' ilI!t!than\ine:~l ';'1 :1 
1wo cas", of severe allergic ('('actiolls I () arll'5unai<' II.,V(-' 
lJeml reported in Thailand," 
Or 153 cllildrCll with malar iiI l'lll'Olll,rl in it rCiliclollliscd COll-
trolled Irial comparing arlesIlI,,,I,, plus alllo<ii;l(IUilll; with 
amodiaquim) alolle, nine chilel!'I'1i (G% I D5% Cl 3-1 I D 
developed a Significant dec",,\sl: ill I ill'il' lIieutrophil cmulL 
Tim:" we're ill! ,mlotiillquine-arlCSUlInlC Zlllli six 011 amodi-
aqllilll' illolle; 'Ill had 1l00Tllai t!ellt rophil COUll!.' l,don; I real-
1 Tlllni. A d"crease In the !lumber of !It'ul ruphil ('1>lls in tlle 
[)lond (m>ltlropel.ia) is associated wilh incr"",,'(! risk 01 
sc:vel"e inft~cl iot IS. 
JJJi'allls horn 10 287 WOllle11 in'ldvt'rlenily eXI'"wd rlilrltlg 
pmgmulCy 10 a m't\S adlllinhtratiOll of a ,illg!l" <lme 01 
arles"II"I" l'lm SP, h~d lliglier I)irtll weigilis 1111111 llios" nol 
expmcd, and Ihere Wtln, no dilTI'l'('llCl" ill tl1l.' propoltion of 
celflgellilal abllorrllalil ie" sl ill iJirllis, al,,)rl ions or neonatal 
dC'alhs belwc:ell expo,sed alld 1I11l:xposed W()(llt'll, ln a 
prospective open-hbcl ,tlldy of pn:gmml WOlnml tmatl'd 
will! arlclIlbillill derivatives (Illl1.Slly artestlliate) 1'01' 5~lQ 
!llllitidrllg-resislani r,dcip,lI'uJ1l llIalaria episodes, t.here was 
110 eviti,:tICe ()r "dYe'lse elTeets, Rirlh OllIcOll!l'" did not 
dllT"r sigllifi('anlly fllllll U)lllllllllJity rates for al)l)r1l011, 
sUllllirtll, or cOllgenital abnml1lalily."1 Aillillllgil tl,eSt' studies 
sugg(,sl Illal artmnisinins may have a rl'lalivl'ly good s,JI't"ly 
pJ()l1il: during pmglj;]Jlcy, olily SO or 1111, WOIllI'11 stlltilted 
were (,xl'0~ecl to the drug during II Ie firsl trim,'Sle!'. 
IInplenlentation Issues 
Th" gaps heiweell Sc;il'lllific kllClwledW' alld IJ<'aliiJ policy as 
w,,11 as betW('l;lllll(:orEtjc:tllwidlil policy !!lld praclice c()lllitllll' 
to widell.'" Allilo!lgll local dlicacy daL1 is rccogni",,:d as '111(:('--
c:ssary pre-requisil(' for 'lIl appm[ll'i'I«' allli E'virlc:nce-b"",d 
malaria [J0licy, I'!ficacy dala alone an, 1101 su[fie Icrti 10 enSU\!; 
!,fTm:1ive policy-making or ilIlplemenlaUo[l, EVC:1I will! ad", 
qual!: dala Oll til" status of anlimalarial drug resislancl" enol''' 
ITIOIIS cilallengc:, face Ihose allClllplllig 10 Ll',e rese'trcl! rf'SlJ!ts 











Effectiveness vs. efficacy 
[')1'<:['1 iV"1 ,,'S, of I I'l'almcnl may be lower Ilian Ilw efficacy 
r"l)(lrIICci ill eli! tical trials ;" a result of poor adlwrl'llu; In 
llierapy, SlltJ-llwrapeulic dosing (usually dOff(' 10 Iintil cusl 
In Ille l'aticnl) , poor 'l",liily medicatioll or greal," dis""s" 
slevmily 111,,11 tll" group sludied. For t:X'lIllPic, arlcTIlellwr-
Ilullefallirillc Heeds 10 he acl!J\i1lisl"md wilh a food or 
drink c()lllaining fal 10 I'l1Sllre adequilte absorption, a par-
ticular challenge for p"Ucnl, suffering from IlaUSC<I or who 
l'allflol ;lilonl or deer,ss SUell foods. Slwiics arc 11.S\1ally con-
ducled in wen··equippcd fac:ililk,s til'lt ;!lso pmvid" furth"" 
\t'ppol'l iv" care, which Ls gene, rally scarce ill malaria 
l'lldenlic counlries. 
Diagnostic challenges 
Mahri'l diagllmis is mmIlly based on clinical symptolW>, 
orten ""sulling ill lllisdiagnosi'i ill l'iltienls prcSl'nting with 
il disc",1' C;lllS('d IJY "!loU",r pathogen thai will 1101 respollci 
10 lll,liaria Iw;lIlllnll!. Til arca" willl higiler intensity malaria 
Irallsllliss;Oll, "ven th" ililrociucliull of 
Curtailing resistance and transrnission 
As clinical tri,lIs lllay ovc:n:stimatc: ill<, valu(' of i\CT in Ihe 
real world, research is Ill",dc:d tu dult:rlllinc Ihe Ilet 1J{:lIelil 
of wide,··sc:ale depluYlllenl of 1I1(',S" drug,s. J\ pro,specl iv" 
study of m'11aria incklc,ncc anel trcalll1('nl WilS COllduckd 
on the Ilorthwest border of Thailand 1.0 assess the ind·· 
dClln: of P. [';,lciparlll1l mal"ria ilnd the lilurill'clilic: ],(':'POIlS-
(', to rncfloquinc treatment (lv(,r 13 y"ars. During Ihis 
tilllt', IIlt,l'loCjuhw resisl.ance was decreas,-,d foll()wing the 
widespn,acl deployment of artc,sllnatc phiS rnd'Juquiu(', and 
111(,1'<' I",s been a sllst,IilH,d d"clillC of "I least six-i'old in I lIe 
illcidence of p, falcipilrulll malaria in I]", study area 
Laboratory sludies confirnwd Ihal the susceptibility of' fal-
cipanml malilriil pmilsites 10 ",cfloqlline iIIlIll'uv<,d sigllil'i-
ccmlly fullowing the addition of arleSllnate 10 nwl'loquinc: 
(peeD.D03) ,'''' Although such a study would I.ake yeill's 10 
rel'licille, the significantly cIecreased rm,laria case luad 
observed in Vielnam and KwaZuhl-t'\latal, Soulh Africa 
folluwing tlIe large-scale impl(']llt:lltalioll of ACTs is 
cncOIlI"lging (Figuf'(' 2). 
dul'illilivl' diagnosis wuuld llol fully 
addwss lilis prohlmn, as Itlany nn1ariil 
inl'l'cl iom 'liC asymptomatic. TillIS I hI' 
lln!)(~lin~ or I)itr<l~ites doe's 1101 r\(:~('(:s­
s;lrily imply thai malaria is the cause 
,..-------------------------'--------
Adverse events 
I;; all' ,,,riOllS adverse el'recls of l.1'eal-
Illl'ni an; unlikdy 10 h" ciclecled in 
ranciollli""d trials involving hundreds 
()f flal ients. H ow"vt:r, a systematic 
review nf oWl' I O,O[)[) pilticlltS n'port-
(,d no instilllccS of severe adverse 
pveIl!.', or loxicity.'" It is irnporlanl 10 
1I0ie thai tilo"f' ill lligl1(;SI risk, inclue!· 
ilq.', p'l:gnant WlllIlt,n, infanls and till: 
iIllnlllIi()COlllpromiSl;d (as a ]'esull uf 
HIV-J\[DS or ll1alll\ltriliull) lllClY be 
,ystl'IIIi1lically l:xciuri"d fl'UIll Ih"ra·· 
pC>lltic ('fficacy sllHUes.Tllls is partiell-' 
Jarly impmlanl fur potclltialIy Ilf,,-
Illreatl:ning "elvers," drcc:ls lilal are 
nol clinically "jJjlilH:nt, such a" neu·· 
trll[lf'llia or Ill'palotuxicily, Boll! 
n'qlJile rOULifH' Jaboralory nlOldlnt ing 
for eildy cic;tcct iUIl, which Is nul 
achieval,Jc; ill most heallh can, facili·· 
tiros silllaicci in Ibe: tropic", 
FIGURE 2. NUMBER OF NOTIFIED MALARIA CASES 
IN KWAZllLUNATAL, SOUTH AFRICA BY MONTH IN RELATION TO 
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Treatment -seeking behaviour 
TIl!' I Jt ·fI('.fkial .,rrcch Oil 'lIltill1'llarLlf resislance and lransmis-
SiOll elleP"II(] Oil l'IlSlll'illg (1);11 Ille Illajmily of f:licipanllrl 
inl,:clitllis 'Jr(' In:al.,cI willi "rlclllhillin-IJdsul c(J!l\hillaliol\.\ 
,mel 11l"1 Ille me: of cilli<'l CUI Ill'lll Ic:nl alol\l; h clll'lailed. Tlds 
is itlll1lcllCc:d by Ihe Irc::tllllclll-",ddng hellaviOlll of patients 
and tlwir alllll'Il;IlCe 10 UlItlpkling malaria tn'alltwnl, as welt 
<tS by Ilw inlensity ur malaria transmission, I n areas of high 
inll:llSily malaria transmission, individllab C<ll'ryillg malaria 
I'ar~sit"s an, ireljllellily aSY"Ij)tornalic ,md are lfius less likely 
10 sec\, Ireallllt'nl, potenUally wsulting in lower ACT cover-
"g':. 11 b CIlC<HIr.11;ing 10 11011' Ilml despite having to carry Ihe 
c"st Ii "'"1S,'I\',,,, Ilw majorily (88.5'Yr,) of symptomalic 
1'<llkll" ill " lVt,.'lll1I1ar ,sludy prtJel'wcl arleSullatc pillS Illull,,-
'i"ill" \1\'('1 iiI(' dJ'llgs they Ilad w,u! before; perceplion ur 
liigll'''' drug <'i'liCdCY was tile n'nSOII give.n 1'01' III<, prc.[en'lIn> 
by lil{)~,t. It, 
Costs 
1)e'pit(: groWillg illlcrll(llioll;iI l'vicll'lIce that ACT is Olll' of 
Illl' f"w "f'['"clive nl\~llSlJn'S avail;lblc 10 "Roll Ba, k 
Malarh", ti,e emls of ACTs (1)(" .Ill ill'lJorlanl ol)si;Kic to 
wid"spn,ad implelllenlaliOil. TIlis rc 11 ('clO, til.., pOllr d(Jctt" 
lllClltalion of Ihe higll '.ocietaJ (\lId eCLJIl(Hnic cost'. associ-
al,'t! witli <llitimal(lri(li resi.\lillll'C, and I.Ill' percepliolls of 
ire"llir":tI'C' providc,r,s awl goverlllllcllls Illal ACT WCHlld 11(11 
be a/Tul'd"ble ur sllstainable ill Iheir n,sollru'-colISlraiJll,,1 
t:flvirolllneIlls. Ho\vever, dccn';l~illg fll;;dill ia Iran<"lnissi(JII 
would resIJl1. in a decrease ill lllalaria case, (lIlli lJospiial 
acilllissiollS, Debying Ille cleveloplnellt or resbtaucc should 
I'wlollg tll1, erfecl ivc lif" or I hus" antimalariah, resultill)', itl 
fewer ir"alrn('nl railines a"d Iherefore fewer deaths and 
pol.enticdly low"r rllillre ('osls. Econornic evaluations are 
IIncic>, way to IlIC'dSU!'t1 III(' cost anel cost-effectiveness of 
illlplc'IIII'lilirtli all ACT lllal"J'ia 1J't,alment policy. Bioluglc,d 
"I "I ,:< I,"omic l[J(JcJt.llillg are aho iJeing used 1.0 explore 
Ilow I(! "I'lillli~,e 11111 dqIloYIIIC'111 of anl m"i"ria]s as wdl "s 
to """ss IIi!.'ir elre-eliV(,II"S.S <l11C1 ill1pact OJ1 direci and indi-
recl C(lsls of rmllari,!.I1:!I' 
Rectal artesunate 
1<:,'('1,,1 'Hlll1illbtralioli or arl('sllnatc as initial ImaUlll'llt 
pI luI' 10 referral makes il I'0ssiblr; 10 plCJvid" a rapidly act-
illg alld effective dnlg 10 palieltls wilh acule malaria wiJo 
an: 11II:llJl" 10 take uIal medication ,mel h'l\'C [10 au".\S 10 
hc'allhcan; faciliUes wlwrc parenteral ,mlim(lhlli'lIIIH'I<I[>Y is 
availalJl,'. S"ppositork, UIlI be safely adminisl"red in mini-
lIJallY-"'lllipped health carl: faciliUes and ""'en Oil ilollle, 
ProVilkd 111,11 cady admillislralion or rectal ilft,'slIliale do,,, 
llllt c!t;ler palic!nls fro1Jl reaching il health care facilily able 
to prnvide 1'111'1 her malal i;; Ir"alnH'nt and <lpl'wpri<lh; SIlP-
pOllive CMe, tllis intC'lvcntion has the pOll'lIlI,,! 10 It.'d\lnl 
III.tLllia-n:iallid IIlOlbidily '"1d lIIorl.ality ill rlllal aleas ill 
Ihe trnpics, Amung the arteillisillill Iic:rivaliw,s, Mll'''''lill" 
Was seieclced on the basis of ils r"pid and IllO"d SfH:clllllll of 
:1111 illlalarial act ivily, nol iablc' aiJslll plioll and IC"""1 ing 
saf<:ly and efficacy profile's in nlllll'aJisoll 10 ollwl' availabl" 
lJ'c;"lllwnts]91i1 /\ Ihermostable suppository forlllulalioll of 
arl.cslInille was chosen because Iinrerrigcrat.ed .)t.()J'agl~ alld 
ca~(' or administ rat ion an: (,.5senl ial wltere facil itie.s an' 
rudiJllelllary, 
MallY pali.:nl.s with potentially life-Ilm;ill.ening nmlalia have 
11 10m severe db,,;)sl' I !Jan Ihose enroll"d in clinica! St.lldi.,s, 
with deep,'r lev('ls of coma, ,'''Vl'l'l' acidosb, ,<,w.re iln;wmi(J 
(Hid illll'ainnelil of plllllIOl!:ll'y awl nll1al fllllCl i011, Altliough 
lilinilllally 11·,lirlC'ci P"'IS()II11l'1 Gill administer al'tcsull(Jl.(' sup-
posiloril,s saldy, staff (aJl(i parents) should 1)(, iliforlllc'd of 
II", 1",,'<1 10 oiJ.s"rvl' 1'01' 111<' I'X]llJi,sioli of "'I']>lJSiloric:s.Tll(, 
lime 10 cI";11 a fever has sOlllctim(;, b,,!:n rq,urteci to be 
sllol'k, with arlernisinin cierivatives Ihan quinine, Although 
npid [,,\'(,1' clearallce is an irupOl'lallt dinical I ll'll di I , it elm" 
not necessarily reflect cure alUl lImy ITl'ill" il raise SC'ILse (Jr 
s,;curily: additional defillitive curaliv,' In',!!ll":lll j'l'1 I lililiS 
esslHllia] "veil if symplulIls mc' ,C'li"vccI. Hc'aitll Cilr" 
providers net-cd lu ensure tilal paliellts or c.Jrt:gi"ers lIml,'r-
slanel Ih" nE't'd fur further ('urativf.' trt .. illIICIl( 'II a rd,'nal 
centre, 
Scaling up ACT 
Tllf; scaling up of art(,misinill-'iJas"d clIIJliJinal ion ther;lpy 
as first-Jille t.reatmconl. policy has fo!]owc,d tI", improved 
clire rates, decreased malaria tlallSlllissiofi and d'c,layt:d 
rt,sisi;lIlce doc\lIlJl!lilcd Oil II", w,;stern border of 
TII(liliHld,',1 Theil: i\ nuw glOwing illtlClTmtio[lal ('unsellSlIS 
thai wide-scale systemal ie: i!1lI'iL'llIl'lltal.ioli of ACT is olle 
of ft~W I:lfectiw: nwaSIlICS IIi"t will ,,"ahle rliaiaria-clIClelllic 
counlritos 10 "ciliC've Ihe alllililiollS goals ,set ill Ahuja 10 
[';'011 I),wk l'vbhlia, l'alliclIl'lr1y II\c goal of CUUilig malaria 
lllllrilidily and murt;dily ill half hv 2[110 I> 
A statement frolll the Vl/orJeI Healill Organisation (\VHO) 
ruieascd on 20 February 2002, n;ClJlIIIJlI:llded Ih'lt: 
"G overnments, , ,ra p id Iy adopt more effective treatments, 
The aim is to provide effective treatment against malilria 
and to slow the spread of drug resistance,,, In particular, 
WH 0 recommends the use of ilrtemisinin-basecl combi-
nation therapy, "1:i 
Tiltl widespread lise oj' ACT, was initially ad()pted ill 
SOllil",,,st Asia, in Thailand and Viet.rlill1l and more 1""(,lIlly 
ill Cambudia, Bhutan and tvlyalllllClr. I\CTs am incTc'asingiy 
bdng recOillmended dsewilcre as first-line treatmenl 1'01' 
1I1wlllllplicalcd malariil iii Soulli America (western h:rJl, 
Slllill,ml, Bolivia, Guy",,,, and Frulch Guyana) iHld ill A[l'iea 
(SOlllll Aflie'l, ZamiJia, C'll)OIl, Bllrllll(li and Zanzibar,!, 
hmelillg by till' Glubal Fund lu FiglJl AllJS,l"ilK:rllllu.sis 











Tile SW·.,,,,,flll translati(Jn of policy into r"actire is 
c:llaJI("'gillg, '111d illlprnv(,llll:Ilts In !.lIt: pllblie health Cilr" 
illfraslrIlCllll(, rccl'lired for LlciliLltilig illh arc beyond Ihe 
""1'00 of Ihis Ch"plcr. HuweV(>r, Ihe IlIost important 
aspecl.s inc!IHI,,: llie proactive guaralltee or supplil:S through 
thL' Pillly illvolvl~IlH'111 of pJl;nlll<lCellUCal services, intl·'llsivc 
Ir,lilling ill sllIall gmllps, on··site slnlclllrcri1fl(Jniloring vis-
il.s, alld III!' physical reIIl()V;ll ['rOl11 "ach facilily of th" <1Illi-
II,,,I;\! ial drllg iJdng wilhdrawn ;Hld ils replacenl!:nt wilh 
tlw II"W trcaillwili. The illlpleIllC'lllal.ioll of cilangc, ill 
Irlaidrid ilcatll1Un1 polk.V h(l'\ IH~cn cornpn)Inh{~d ill cuun-
Irks with()ut 111(: stalT 'lIIcl l'Cesollrccs 10 do thh (ill II,e scalP 
IllCcd"d 1.0 illSuru " C()1111'1cle switch ill drugs (VVillia1l1s 
HJ\, 11!1j>llhlislll'd c1;ltd 2002). Thus, IllIplclllelltatiOJI plam, 
,11Cllild I)c dIClfied wdl III "dvallce or the: ddle of IllIl'le·-
111<'lIlal iOll, so Illdl. adequilk htnds me icicillifi"d 10 ass;sl 
wlliJ acldiliomil demands ()II already limilc,d flCCl\lh C"I" 
CHALLENGES/NEXT STEPS 
Tllt,n, llas ["'C:!I a wC'icolne illClcas" recently in fllndillg for 
bot Ii II II' wide-scale 1'11111 ie sector illlplerneni alion or 
eff<:cliv(' casco !1lanagullt:lll. and for Iii" cOInjlH'hensivr, 
['v,iIllClI iom of SUcil inlcrvent ions wit hill the Ilornl,d 
c(JIII"xl or lIS". CllrlSenSllS is growing regarding the i11l1'or-
!anl rule of arft:luisinillS in I11,darla case.: nlflllagt:Hlellt, par·· 
Ilcula!ly for Ihe lise of ACT as !'irsl-Iilll' Ileatm,ml or 
IlJlC(lJlIplic;llcd mil!;" j" and ror Ihe n'('t;lI adillinisiralioll (If 
"rl"sunal" 10 patkll" wllU are ulIal)'" 10 toleralL' oral 
Ir";llwenl aJilI do 1101 !lav!' ace"ss to ilUr:ctable tn,;,lm'''lt, 
Tilere ,lJ't" ilnwc,vcf, a nUII1iwr or 'lUCStiollS tl1'll need to he 
H's"I""ci to oplilllh(' tilt: puhlic Ileilith iwnenL, of titese 
,II al l'g ics. 
J)c'pil" II:" ('vid"ncc, ;Ivailahle to dal,'. COllcen, has been 
l:xpn"",'d Ih"l Ille puq)"r1('d I,enefib 01' J\CT havu nOI. y"t 
I """ I prov" I I ill Africa, Ii '.c, Tlth has llHlliv<lled hrgc-sc;iI,' 
('OlrlllldlC'flsivlO cvaitl<ltiollS of Ille staged inlllldliction or 
ACT i11'11 ;<n' currr'nlly underw<lY in rh(c pullik seclor in 
SCHlilu,nl and East Africa.'" TIH~S" studies aim 10 cSlablisl1 
wllctlwr ACT is cusl. dl(.'cl.ive (or even cosl-saving) as well 
a,S wildl",,, J\CT improves Ireatmenl ((11(, riltes, rt'duces 
lualari" InlllSmi\sioll, d"LTeascs ruoriJidily and lIlorlall!y 
<lIld dday.s I'll<' l'.lIicrgellcc or ,.,,,htance 10 arford;lill" nrst-
lin(' '"IIi-lnalarial Iherapy wltiJill 111(' 1101Tllai c"ult:xl of US" 
ill ;\1'1 ica, TII(''': Slll"il:, als" hope to "sUlblhh how II"al.-
1lIl:lll·s""',ing IlCllilvillul ;lllci p~ti(,lll aLlllerene" inriul'lJ(:e 
II 1'Ilblic Ilcalill impact or ACTs. 
T()uls f()r 111111liloring cirug safl:ly and ;\(lh(:II:II(," wilh 
t,.",,11111',,1 11('"rI sln:nglhclling, particularly ill n'S(llIlTl:-pour 
settings. 1\llhough IlIon.' saldy dala h 'Ivailaill" regarding 
arh'luisinin derivati""s I han olher anUrn'llar ials, CClIIC(:n JS 
lugarding sarHy ill high-risk groups, spt'cifically I'n'gnanl 
WOlIlen and i"ran!.s, require flllther lllonitol ing. As Ille.s" 
sl1(:ci;;1 risk gnHlp.s carry tl,,: highest tJlmlt:u uf m~laria, 
addressing Ihis need is urgent. The dficacy alill safety of 
ACT 1(". HlutinEl inlennillenl I.n:atnll:nt through .lJlt"llalal 
and vaccination pmgrallllIltOS are currenlly iJeing stuclit:cl. 
R"d;J1 arl"sun~rl: hilS bc~en sliuwn to clear l'iIlasitcs mure: 
rapidly II mn parenlt:rid quinine, allll!lugil lids dom lint 
nuc{~\~:trily lead to a cliJl1cal advantage or a <.k'<'Tea\(' iu 
lII111talily Llrg<' ranci01l1is<:rI placci)(J-conlrolicci silldi", an' 
lIJ1(lcrway ill J\fric.a emd A,sid to t:sL.lJlisli wlwllll'C. tile 
adl11inislral ion or rectal artesLlnat(·, 10 I'"t i<:lits lillabl" 10 
l!ll"latc' oral treat 11 IPIlI in bClsic Iwalth ulre racilil ies wlir:J<' 
pan'I,ler;,1 treatlllC'nl is llol dv;dlaillp, decn:aSt's maJaria-
[clilted hml'ital admissions and d'"dl.h,. Th",!: 'lwlie5 arc 
being cond'lcleci without. olher interventions, so they will 
reflect b"rwfits within Ihe lIormal cOllit'xl of lise where 
he"llil care providers face Ill111WlUll' cilalkngcs. TtI,,-,!: 
illclllcic llie use or P1CSUfllpth·c or clhlic:al raUlcr lli'lli 
definilive diagllosis or malaria, lire high 1'J<,valenc<: of 
HIV/AIDS and HlalJllllrition, dllal infections al pnOSe111a-
lion (".g., meningitis), and til" wid(:spn'a,j use ur C{lIICOlni-
lant Illf:dic,,1 ion (traditional and Vv'l',krn me<iicil"osj, 
Concern that the reclal adlllinistral ion (If all"sltnatl' 11I"y 
dday seeking dpfinilive lrpallJll,nt ilnd supporlive UlI" if 
needled, or thilt rectal ;01'1 ('S(ll I;;t (" may be i<'ss reliably 
al""";)(,,I ill palil'IJI' with morl' .\l'v(m' In'llaril!, sit()IJid "l:,o 
I", answered t.Immgh tll"s" Sllllli,·:s. 
Changing nalional m,dari;l 11l',lI11WIJI policy could 1)(, lile 
sillgle interventiun that is I I j(),S I likely 10 clillaJlc(: access to 
J\CT, whether adlllinis1ered ((rally 1'01' uncomplicated 
rnalaria or recta!!"\! 1'01' rnOle severe LTlaii1rhL Howp\,pr, \Vhdl 
is lUll known is how l1mcl1 "videllC<' i, rt"qnin:d 10 chang" 
existing national treatmenl policy. fll cOllnlrics Ihal havc, 
(I ifTcfl'lIt 11m ISlllissiun prol'il"S, evi(j"n, 'U flOllI ow.' or I W() 
IuCit! slutlics Inay nol be slIlTici"nl 10 convillce flolicy 
mal("rs of I he: ncul for a llill ional levd char 'fie of policy. 
The: glliddiliCS most widely '15(:,1 art: 11m", of Illl: vVHO, 
widell rct:ollllllenris il1lplmnt:nt.ing Ii malaria Ileallllelil 
policy change when first-line IrcallllCl,1 rails in 25 'X, or 
l'aliclIls; this recommendation is considered 1.0 COlltriilute 
to the prolonged lise or inclTec:liv" malaria treatment, par .. 
I iClll;lr1y .,inn, Ihe: reCOllll1J(,"tied 14-cJay follow-up under 
",lil""tl.'S rusi.slallel:." Up·lo d;II." imernCiI iOlliil gliidelilll·:S 
0" wll,,1 COllslilut",s i\dec[1lilte sUllinel survdlLlllCe fOi 
dc., I.e rr nil Iillg malar ia trcal Ifll'nl dlk;wy and rlw I,'vcis of 
n~sisl"nCl' ill which tile c1laIIW' [,roccss ,should 1)(: illitidlcd, 
wOlild fllcililall' r;dioual antilllalarial drllg policy Illaking. 
Club«1 agl:ncies tasked witll !l1;·,lariil cOlllml sliolJld lake a 
Jt,;1C1 ill preparing sllch guidelines, Once a rnillilfllllll Sl;lll·-
(lim I or sllrvf'illancl: is agmcd UpOIJ, acieqll<ltc r!'SOllree, will 










Til" IIIOSI i'n'quclllly cited (Jbstad" to cnh<llicilig <lCCCSS 10 
!\CT lias 1)("'11 ils ,,,tl"lalltially higher COSI pt,r I n,al!!"'lll 
(,,,,,,St) wllell cumpan,c1 10 chloroquille or SP Economic 
;lIld s()"itolal cosls of Jllt'lleelive In·"lllH'lli [,olicit'S ""cd 10 
ill' ddincd s() that Illes" (an I", COlJlpareri willllh'e cosls ur 
'III /\CT policy cilelll;":C. HOW(;VCl, il h likely 1l,,'11 Ihe cosi (Jf 
"leI! a policy cJl<lllgl' will nol ill' :dfonlahle 10 lIl<1ny lllalilf-
ii.I (~Il(h'l!1ic C:()liTltrh:~, iHld illll'l'll;lli(Hlat t\IfHlillg 10 slipporJ 
Illh Ch:lllgl' is lJ('c(kd. II is of concern Ill:11 Ille Clohal 
Fllll' I III t,'iglll 1\ IDS,TlIbcrClIlosb <mel Malaria is 
Lurr"lIlly '1"'lIt!illg IrlCJl'(: ill tile procurement of chloru-
qUille II"Hl of ACTs ill Africa, despil.l' ("tablislwd wiri(;-
~pn'(Hl cldoroqllil!c n~\isjflllce arH_1 an as~oci(lted 1I1CTcrl.Se in 
Ill()l\;lliry.'" This hillcling should rallwr \)(' targeled 10 
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11 NI"N!{)1l P~-J, AJlnq~ liJ, (:hU:ra[<I!I \V D()f](torp A, !<, 
SibnHJI I( '];'(·r.qldllg p. SI\fill!l,llntlrl t;ko1 y, LO{)<ln-'e,<';llwall NJ. 
1< all.dnl))L~('d (olllparis111l ()f ~irt('suncdp and quinine ill tlw tr0<it!I\f'nt nf 
'OWfI' fl)'fl,oI i;). ('Iifl I d,', 1 1)1,.1'111):13'7(1): 7·· J fl. 
!:l I ,tlXl'rYlhnrg('r C, 'l hw,d !<I", l".z;dmond SD, ChongE.llp1Ktjaisiddhi' [', \Nhitt' 
NJ. Or;l! arl(~sl1nal(· in Lht' tn~<ltr)lf'nt of 
f:'Ilr jpanlll1 malari(1, Am J Tmp t'v1!~d I-lYe. 
pr"vidul with elrl~c1ive malaria tl'l':Jt!rH'IIi. Thi, will rC'lllil'f' 
n.,visioll uf Ill" proCl'c1uw fot leclillic.! revi<'w of fllilding 
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Appendix 2 Forms 
Subject Information and Consent Form: Artesunate study 
You have malaria, which is a serious disease. We are conducting a study on a new drug for treating 
malaria which is called artesunate, and we would like to include you in this study. You will be treated for 
this disease whether or not you choose to participate in this study. You are free to ask any questions 
about the study at any time. 
This new medicine, artesunate, has been found to be effective and safe in treating malaria in other 
countries, but tlas not yet been used in South Africa. This study may help artesunate to become more 
available in South Africa and other countries in Africa. We plan to include 100 patients with malaria in 
this study Patients entered into the study will be closely monitored. Regular blood tests will be taken to 
see what is happening to these medicines in their body, and how quickly the malaria is going away. 
Some patients will be given the usual malaria treatment, so that we can compare the results of the old 
and new treatments. The sickest patients will be given quinine (the usual treatment) in a drip at once, 
with or without the new medicine, artesunate suppository. These patients will need to stay in hospital for 
a week. 
The less sick patients, will be given either artesunate suppositories OR quinine injections on the first day 
followed by sulphadoxine / pyrimethamine tablets (the usual treatment for patients who are well enough 
to take tablets) on the second day. Anyone who does not get better will be given a quinine drip. These 
less sick patients only need to stay in hospital until they are well enough to go home. 
Artesunate has been found to be safe in the patients who have been treated with this drug in other 
countries. But, since this is a new medicine, we will examine you very carefully for any side effects. 
These may include ctlanges in your nervous system, which have been seen in animals (given much 
higher doses than we will be using), but not in humans. The new treatment may also cause nausea and 
vomiting. 
We would like you to come back for a check up after one, two and six weeks, to make sure that you are 
well and that the malaria has not come back. We will pay you R50 at each visit to cover your expenses. 
Please note: 
,. Women who may be pregnant should not enter the trial. 
.. Those who have taken other malaria medicines in the last 24 hours should not enter the trail. 
,. Only patients between 16 and 65 should enter the trial. 
.. Those allergic to quinine or artemisinin derivatives (e.g. artemether) should not enter the trial. 
.. Those patients who have had any rectal surgery or disease of the rectum should not enter the trail. 
------_._._ .. __ ._-_ .. 
By signing this form, I agree to participate in this study; or the next of kin 1 legal guardian agrees that the 
patient named participates in the study; or the witness agrees that the patient has given verbal consent to 
participate in this study. 
Patient surname Patient first name 
",." ... ",,,.,, .•••••••• " ...................................... « ••• ""'" •• ,,"", ... " .••••••••• " .. 
Next of kin 1 legal guardian 1 witness surname Next of kin 1 legal guardian / witness first name 
............. """ ...... " ... ,,,''',, ... 
Patient / next of kin / legal guardian / witness Date 










Appendix 3: Normal ranges for laboratory values 










Appendix 4: HPlC-ECD Methodology and Quality Control 
1. ANALYTICAL METHODOLOGY 
Artesunate (AS) and dihydroartemisinin (DHA) were determined in plasma by a 
specific and sensitive high-performance liquid chromatographic method with 
electrochemical detector operating in the reductive mode (HPLC-ECD) method ['I]. 
However the published method has been modified and is briefly summarised below; 
a detailed description of the revised methodology is given in the Standard Operating 
Procegures of the Centre of Drug Research, Universiti Sains Malaysia (USM) (CDR-
SOP.ALU2). The lower limit of detection for both AS and DHA was 4.0ng/0.5ml. The 
assays were conducted according to Good Laboratory Practice (GLP) procedures 
and requirements at the Centre for Drug Research, USM, Penang, Malaysia. 
After extraction from plasma, AS and DHA were analyzed using Hypersil Butyl C4 
column and a mobile phase of acetonitrile- 0.05 M acetic acid (40:60 v/v) adjusted to 
pH 5.0 with electrochemical detection in the reductive mode. The mean recovery of 
AS and DHA over a concentration range of 50-200 ng/ml was 75.5% and 93.5%, 
respectively. The within-day coefficients of variation were 4.2-7.4 % for AS and 2.6-
4.9% for DHA. The day-to-day coefficients of variation were 1.6-9.6% and 0.5-8.3%, 
respectively. The minimum detectable concentration for both AS and DHA in plasma 




Decahydro-3, 6, 9-trimethyl-3, 12-epoxy - 12H - pyranol [4,3-j]-1, 2 - benzodioxepin-
10-01, hydrogen slJccinate. 
Molecular Formula: C19 H28 0 8 
Molecular Weight: 384.4 
Control number: 2019261 
Supplier: National Institute of Drug Quality Control, Ministry of Health, 
Vietnam. 
DifJydroa rte m isin in 






A rte misin in 
C1S H24 Os 
284.4 
DHA0010 
National Centre for Genetic Engineering and Biotechnology, 
Bangkok, Thailand. 
(used as an internal standard) 
Octahydro-3, 6, 9-trimethyl-3, 12-epoxy - 12H - pyranol [4,3-j]-1, 2 - benzodioxepin-


















Appendix 4: HPLC·ECD Methodology and Quality Control 
1.2 QUALITY CONTROL SAMPLES 
For within-study assay validation, quality control (QC) samples were prepared one 
day prior to study sample analyses, by spiking freshly thawed drug free plasma 
(0.5ml) with known amounts of both AS and DHA A minimum of 6 QC samples was 
prepared. The resulting concentrations were in the range of 80ng to 600 ng/0.5ml. 
The QC samples were stored below -70 DC in silanized tubes pending analyses. For 
each batch of study samples one set of QC samples was analyzed. 
1.3 CALIBRATION SAMPLES 
Calibration samples (C) were prepared one day prior to sample analyses by spiking 
freshly thawed drug free plasma (O.5ml) with known amounts of both AS and DHA 
The resulting individual values of concentrations of artesunate and dihydroartemisinin 
were always in the range of 10ng to 800ng/O.5ml, above the lower limit of 
quantification. The calibration samples were prepared in a similar manner for each 
batch of study samples. The calibration samples were stored below -70 G C in 
silanized tubes pending analyses. Prior to sample analysis, three calibration curves 
with three sets of QC samples were analysed for a pre-study validation exercise. The 
results of these experiments are documented on site in CDR File (Pre-study 
Validation: Artesunate). On the day of batch sample analyses, QC samples, 
calibration samples and study samples (clinical samples) were spiked with known 
amount of intemal standard (artemisinin) before undergoing sample processing. 
Different stock solutions of AS and DHA were used for the preparation of QC and 
calibration samples. A qualified person not involved in the study did the preparation 
of the stock solutions for QC. 
1.4 SAMPLE PROCESSING 
Tubes containing 0.5ml of QC samples and calibration samples, which were stored 
below -70 0 C together with study samples (clinical samples), were thawed at room 
temperature. Aliquots of 0.5ml study samples were pipetted into silanized tubes. 5 
fl.1 of the working solution of the internal standard (40ng/fl.l) was spiked into all the 
tubes containing QC, calibration and study samples. The mixture was vortex-mixed 
for 30 seconds. Appropriate amounts of ultra pure water were pipetted into each of 
the QC, calibration and study samples in order to obtain a final volume of 1.0m!. The 
mixture was vortex-mixed for 30 seconds. The samples were then loaded onto GIS 
SPE cartridges, which had been conditioned with acetonitrile and water (each 1 ml x 
2). Each cartridge was washed with 1-ml water. Elution was carried out with 3 
sequential applications of O.5ml acetonitrile. The eluents were collected into a test 
tube and dried in a gentle stream of nitrogen at room temperature. The residue was 
reconstituted in 100111 of ethanol-water (50:50 v/v) and left for 18hr at 4°C in order to 
allow stabilization of the ratio of the a and ~ isomers of DHA. Twenty microlitres was 










Appendix 4: HPLC-ECD Methodology and Quality Control 
The chromatographic conditions were as follows: 
Stationary Pilase: Hypersil butyl (C4) column, 250mm x 4.6mm Ld. x 5~Lm 
Flow rate: 1.5 ml/min 
Mobile Phase: Acetonitrile: 0.05M acetic acid (40:60, v/v) adjusted to pH 5.0 
with 1.0M sodium hydroxide 
Detection: Electrochemical detector operating in the reductive mode. The 
detector was set at 50nA. 
1.5 DATA PROCESSING 
The concentrations of unknown and QC samples are determined by linear regression 
analysis (function y :::: a + b*x ; weighting factor 1/y2). The peak height ratios of the 
drug (AS and DHA) to the internal standard (y) were plotted against the 
concentrations (x) of the drug (AS and DHA). Calculation of results was carried out 
by use of a specific worksheet programmed in SPSS® software (SPSS for 
Windows®, version 6.0, SPSS Inc., USA). 
The laboratory personnel reviewed all analytical data for completeness and accuracy. 
The Principal Investigator for this Bioanalytical part of this study, Dr. Surash 
Ramanathan, finally checked the raw data (chromatograms). CDR Quality Assurance 
Group crosschecked data entered manually into a database against the source data. 
Concentrations below the limit of quantification are designated as '<LOQ'. The 
abreviations 'SS' and 'PS' were used to designate concentrations that could not be 
generated. 'SS'-sample spoilt referred to samples which, following extraction, were 
not suitable for injection into HPLC i.e. the sample was not clean and if injected into 
the HPLC, would damage the analytical column, as well as, generate a 
chromatogram that would be of difficult integration. 'PS'-peak spoilt referred to 
samples that were injected into the HPLC, but the peaks generated following a HPLC 
run were not well resolved to baseline, not symetrical or properly integrated by the 
integrator in order to be accepted as valid drug peak. Samples designated as 'PS' or 
'SS' were required to undergo repeat analysis if there was a sufficient amount of 
plasma volume for extraction. 
All concentrations related to AS and DHA. The final concentrations were rounded to 
one decimal place. 
1.6 CRITERIA FOR ASSAY PERFORMANCE AND SAMPLE RE-ANALYSIS 
An individual sample was subjected to repeat analysis if the sample was dirty and not 
suitable for injection, sample concentrations fell out of calibration range, there was 
peak spoilage owing to interference from endogenous peak orland peak of interest 
does not resolve to baseline. As for batch sample analysis, it was to occur if less than 











Appendix 4: HPLC-ECD Methodology and Quality Control 
DRUG ASSAY AND VALIDATION: RESULTS 
2.1 Assay Performance 
Calibration 
The calibration curves for artesunate (AS) and dihydroartemisinin (DHA) were linear 
with a coefficient of correlation ranging from 0.980057 to 0.999997 and 0.979582 to 
0.999998 respectively. 
Within-study assay validation 
Within-study assay validation was performed by analyses of the QC samples 
together with the study samples. 
The method validation data are summarized in the tables below: 
Table 1 a: Summary of within-study assay validation for artesunate 
Nominal cone. In QC Number of Mean recovery Precision* 
sample [ng/0.5mll determinations [% of nominal conc.] [%1 
80 106 104.3 8.4 
300 136 99.8 9.7 
600 128 97.6 10.2 
.. 
.. coeffiCient of variation (100 * standard deViation/mean) 
Table 1 b: Summary of within-study assay validation for dihydroartemisinin 
Nominal conc. in QC Number of I Mean recovery Precision* 
sample [ng/O.5ml] determinations i [% of nominal conc.] [%] 
-SO 121 107.4 7.9 
300 146 100.9 8.2 
600 142 99.1 9.0 
.. 
.. coefficient of vanat,on (100 * standard deviation/mean) 
